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Abstract 
Type 2 diabetes is a risk factor for the development of cardiovascular disease. 
Recently, the term diabetic cardiomyopathy has been proposed to describe the 
changes in the heart that occur in response to chronic hyperglycemia and insulin 
resistance. Ventricular remodelling in diabetic cardiomyopathy includes left 
ventricular hypertrophy, increased interstitial fibrosis, apoptosis and diastolic 
dysfunction. Mechanisms behind these changes are increased oxidative stress 
and renin-angiotensin system activation. The diabetic Goto-Kakizaki rat is a non-
obese model of type 2 diabetes that exhibits defective insulin signalling. Recently 
two interconnected stress response pathways have been discovered that link 
insulin signalling, longevity, apoptosis and cardiomyocyte hypertrophy. The 
insulin-receptor – PI3K/Ak –pathway inhibits proapoptotic FOXO3a in response to 
insulin signalling and the nuclear Sirt1 –deacetylase inhibits proapoptotic p53 and 
modulates FOXO3a in favour of survival and growth.  
Levosimendan is a calcium sensitizing agent used for the management of acute 
decompensated heart failure. Levosimendan acts as a positive inotrope by 
sensitizing cardiac troponin C to calcium and exerts vasodilation by opening 
mitochondrial and sarcolemmal ATP-sensitive potassium channels. 
Levosimendan has been described to have beneficial effects in ventricular 
remodelling after myocardial infarction. 
The aims of the study were to characterize whether diabetic cardiomyopathy 
associates with cardiac dysfunction, cardiomyocyte apoptosis, hypertrophy and 
fibrosis in spontaneously diabetic Goto-Kakizaki (GK) rats, which were used to 
model type 2 diabetes. Protein expression and activation of the Akt – FOXO3a 
and Sirt1 – p53 pathways were examined in the development of ventricular 
remodelling in GK rats with and without myocardial infarction (MI). The third and 
fourth studies examined the effects of levosimendan on ventricular remodelling 
and gene expression in post-MI GK rats. 
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The results demonstrated that diabetic GK rats develop both modest hypertension 
and features similar to diabetic cardiomyopathy including cardiac dysfunction, LV 
hypertrophy and fibrosis and increased apoptotic signalling. MI induced a 
sustained increase in cardiomyocyte apoptosis in GK rats together with 
aggravated LV hypertrophy and fibrosis. The GK rat myocardium exhibited 
decreased Akt- FOXO3a phosphorylation and increased nuclear translocation of 
FOXO3a and overproduction of the Sirt1 protein. Treatment with levosimendan 
decreased cardiomyocyte apoptosis, senescence and LV hypertrophy and altered 
the gene expression profile in GK rat myocardium. 
The findings indicate that impaired cardioprotection via Akt – FOXO3a and p38 
MAPK is associated with increased apoptosis, whereas Sirt1 functions in 
counteracting apoptosis and the development of LV hypertrophy in the GK rat 
myocardium. Overall, levosimendan treatment protects against post-MI ventricular 
remodelling and alters the gene expression profile in the GK rat myocardium.  
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1 Introduction 
Diabetes is an increasing health concern in most developed countries with 
prevalence reaching an estimated 10% of the population. During the last few 
decades the increase in the number of patients with diabetes has accelerated and 
the latest estimates depict alarming numbers for the future: within the next 10-15 
years the number of patients with diabetes may be twice of that today. Diabetes is 
a burden to society and it has been calculated that up to 15% of healthcare costs 
in Finland may be attributed to the care of patients with diabetes (Current Care 
guideline for diabetes, Duodecim 2009). The majority of these costs arise from the 
care for diabetes related complications. Diabetes is associated with several 
complications but the main cause of death for type 2 diabetic subjects is of 
cardiovascular origin.  
Type 2 diabetes is often associated with risk factors for cardiovascular disease; 
these so called co-morbid states include increased blood pressure (hypertension), 
dysregulation of lipids in the blood (dyslipidemia) and coronary artery disease 
(CAD). Over the last decades the concept of diabetic cardiomyopathy has been 
introduced (Rubler et al. 1972; Regan et al. 1997). This describes the 
independent adverse effect diabetes has on the myocardium (i.e. the heart as a 
muscle). The rationale for introducing this term was based upon findings showing 
that, when adjusted for the co-morbid states mentioned above, diabetes is a 
positive predictor for cardiac disease. Diabetic cardiomyopathy is associated with 
various changes in the heart including increased growth, an increase in the 
formation of connective tissue and an increase in the rate of cell death. These 
changes alter the structure of the heart and therefore, its function as a pump is 
compromised. Diabetic cardiomyopathy is associated with diastolic dysfunction 
owing to the increased stiffness due to hypertrophy and connective tissue build-up 
(Regan et al. 1972). In diastolic dysfunction the heart is unable to relax and blood 
flow into the ventricles is decreased at diastole. Later, systolic dysfunction may 
develop. At present several mechanisms involved in the development of diabetic 
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cardiomyopathy are known. Changes in energy source utilization, generation of 
free oxygen radicals, activation of the renin-angiotensin system (RAS), 
crosslinking of excess glucose to structural and functional proteins such as 
collagen (glycosylation) and ryanodine receptors (RyR) and mitochondrial 
dysfunction are all known to enhance the development of diabetic cardiomyopathy 
(for a review, see Dobrin et al. 2010). 
Lifestyle changes provide the cornerstone in both the prevention and treatment of 
type 2 diabetes. However there is also a need for new and effective 
pharmacological treatment for the disease and the arising complications. When 
treating the complications related to diabetic cardiomyopathy there are strikingly 
few drugs available. The calcium sensitizer Levosimendan is a novel inodilator 
used for the short-term treatment of acute heart failure (for a review, see Milligan 
et al. 2010). The mechanism by which levosimendan acts is unique from the 
traditional positive inotropes, such as dobutamine and dopamine. Levosimendan 
has vasodilatory effects in addition to its positive inotropic effects, and hence the 
term inodilator is used. At present, levosimendan is used clinically for acute 
decompensated heart failure. So far there have been few studies concerning its 
use in diabetes-related cardiomyopathy. 
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2 Review of the literature 
2.1 Type 2 diabetes 
2.1.1 Definition and etiology 
The trigger for type 1 diabetes is a rapid loss of insulin–producing cells from the 
islets of Langerhans in the pancreas. The disease is presented when endogenous 
insulin production has decreased significantly. Typically type 2 diabetes is 
characterised by an increase in blood glucose with sustained endogenous 
production of insulin. The onset of the disease is slower in type 2 diabetes. 
However, the division between type 1 and 2 diabetes is artificial and is useful only 
at the extreme ends of the spectrum as most patients develop aspects from both 
types. For simplicity and lack of better option, it is customary to use the 
abovementioned division. Type 2 diabetes is a heterogenous disease with elusive 
diagnostic criteria. A typical subject may be middle aged, obese, hypertensive and 
dyslipidemic. However the increased occurrence is rapidly broadening the 
spectrum of afflicted people. Etiology is multifactorial with both genetic and 
environmental factors playing a role in the pathogenesis. Obesity is a known risk 
factor for insulin resistance and at present patients who are prediabetic (impaired 
fasting glucose or impaired glucose tolerance or both) are commonly overweight. 
Insulin resistance and a relative insulin deficiency are common in newly 
diagnosed type 2 diabetic patients. Relative insulin deficiency indicates the 
inability of tissues to utilize insulin at normal concentrations due to insulin 
resistance which results in a subsequent increase in insulin production. In the 
long-term the compensatory increase in insulin secretion may be followed by a 
decrease in insulin production leading to overt insulin deficiency. Hence the older 
term non-insulin dependent diabetes mellitus (NIDDM) is an unsuitable 
description for type 2 diabetes. 
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2.1.2 Diagnostics 
Although precise diagnosis of type 2 diabetes is difficult, there are some 
established laboratory procedures that are commonly used. At present, 
established criteria for diagnosis in a symptom–free individual are a fasting 
plasma glucose concentration of >7mmol/l or failure of plasma glucose to 
decrease under 11 mmol/L 2h after an oral glucose tolerance test. In an individual 
with classic symptoms for diabetes, such as polyuria, increased thirst and/or 
unexpected weight loss, a non-fasting plasma glucose concentration of >11 
mmol/L is diagnostic. Individuals with impaired fasting glucose (fP-Gluc 6.1-6.9 
mmol/L) and/or with impaired glucose tolerance (P-Gluc 7.8-11mmol/L 2h after 
oral glucose test) are considered to be in a prediabetic state. Measurement of 
glycated haemoglobin (HbA1c) is used to follow response to therapy in diabetic 
patients. For diabetic animal models there are no established diagnostic criteria 
and thus when evaluating diabetes in experimental rats the corresponding human 
threshold values are widely used. 
2.1.3 Prevention and treatment  
Type 2 diabetes is foremost a disease of lifestyle. In order to slow down the 
number of incidences of diabetes today there are several programmes for the 
primary prevention of type 2 diabetes. These share the aim of increasing 
awareness of the beneficial effects of a healthy diet and exercise. Patients with 
the metabolic syndrome have an accumulation of risk factors such as 
dyslipidemia, obesity, hypertension and insulin resistance, and should be among 
the primary targets for prevention of type 2 diabetes (for a review, see Tuomilehto 
2005). Treatment options for type 2 diabetes include changes in lifestyle, oral anti-
diabetic pharmacotherapy and sometimes insulin therapy. It is recommended that 
at time of diagnosis, the oral antidiabetic drug metformin is started. As add-on 
therapy there are several other oral anti-diabetic drugs (Table 1). Insulin treatment 
is indicated for insulin deficient type 2 diabetic patients and/or for those whose 
hyperglycaemia is unresponsive to oral anti-diabetic drugs. In some cases insulin 
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Table 1. Pharmacological management of type 2 diabetes 
Class Drug 
Effects on S-
insulin 
Indication Mechanism in brief 
Adverse effects in 
brief 
Biguanidines Metformin No First-line at 
presentation of 
diagnosis 
Activation of AMPK 
suppresses hepatic 
gluconeogenesis 
Well tolerated in 
general, lactic acidosis  
Thiazolidinediones Pioglitazone 
Rosiglitazone* 
No Second-line PPAR-gamma  
activation 
Worsening of heart 
failure, AMI, fluid 
retention 
Gliptins Sitagliptine 
Vildagliptine 
Saxagliptine 
Glucose –
dependent 
increase 
Second-line DPP-4 inhibitor, GLP-1 
increase 
Long-term effects 
unknown 
Meglitinides Repaglinide 
Nateglinide 
Glucose –
independent 
increase 
Second-line Blocking K+ -channels in 
pancreatic beta cells 
Hypoglycaemia 
Sulphonylureas Glibenclamide 
Glimepiride 
Glipizide 
Glucose –
independent 
increase 
Second-line Blocking K+ -channels in 
pancreatic beta cells 
Hypoglycaemia 
Incretin mimetics Exenatide 
Liraglutide 
Glucose –
dependent 
increase 
Second-line GLP-1 mimetic  Nausea and other GI 
adverse effects, long-
term effects unknown 
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Class Drug 
Effects on S-
insulin 
Indication Mechanism in brief 
Adverse effects in 
brief 
Long/intermediate- 
acting insulin 
Glargin 
Detemir 
NPH 
 
Adjunctive for treatment -unresponsive 
hyperglycaemia and/or insulin deficient 
type 2 diabetes 
20-30h duration 
12-24h duration 
12-20h duration 
Hypoglycaemia 
Short-acting insulin Humulin 2-4h duration Hypoglycaemia 
Rapid-acting Aspart 
Lispro 
10-20 min. to start Hypoglycaemia 
*Withdrawn 
 
(Modified from Goodman & Gilman’s the pharmacological basis of therapeutics, 12th ed. 2010). 
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treatment may be first-line therapy in type 2 diabetes, e.g. when plasma glucose 
concentration exceeds 15 mmol/L, HbA1c is over 10% and/or patients show 
unintentional weight loss. The common co-morbid states in type 2 diabetes are 
commonly treated with statins (dyslipidemia), ACE inhibitors/ARB:s (hypertension) 
and mini-acetylsalicylic acid (anti-thrombotic). The following laboratory values are 
aims for subjects with diabetes (Current Care guideline for diabetes, Duodecim 
2009): HbA1c (%): <6.0-7.0, fasting glucose: 4-6 mmol/L, postprandial glucose (ca. 
2h after last meal): <8 mmol/L, LDL cholesterol: <2.5 mmol/L, <1.8 mmol/L if 
known arterial disease, blood pressure: <130/80.  
2.1.4 Insulin resistance 
Insulin is a hormone secreted from the pancreas and its main actions are 
anabolic, i.e. it builds up energy stores. In carbohydrate metabolism its main role 
is to increase glucose uptake from blood to tissues. Insulin resistance is one of 
the hallmarks of type 2 diabetes and at present it is assumed that insulin 
resistance develops years before hyperglycemia and the onset of clinical 
symptoms. In short, insulin resistance is a state where the glucose lowering effect 
of insulin is reduced. This occurs due to the organism’s inability to utilize glucose 
in an insulin dependent manner in organs such as skeletal muscle and adipose 
tissue (Becker 2001). In the insulin resistant liver, the normal increase in glycogen 
synthesis and storage and the suppression of glucose production is absent. The 
insulin resistant state triggers a compensatory increase in insulin production in 
pancreatic beta cells. After a period of hyperinsulinemia, a characteristic reduction 
in insulin production slowly occurs, due to beta cell failure, at which time insulin 
substitution therapy may be needed. 
A high degree of visceral fat, independent of age, is associated with an increased 
risk of developing the metabolic syndrome including insulin resistance, 
hypertension and dyslipidemia (Abrams et al. 2010). It has recently become clear 
that adipose tissue secretes high numbers of cytokines (adipokines) that are 
metabolically active in most organs of the body. The adipokines and their roles 
implicated in the development of insulin resistance include decreased levels of 
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adiponectin and increased secretion of inflammatory mediators IL-6 and TNF-
alpha together with leptin and resistin (for a review see Dobrin et al. 2010). In the 
liver the accumulation of fat presents itself as non-alcoholic fatty liver disease 
(NAFLD). In NAFLD an increase in lipolysis leads to the accumulation of fatty 
acids and their by-products which may further disturb insulin signalling 
contributing to insulin resistance in the liver. The insulin –regulated Glut4 protein 
is the most important glucose transporter in striated muscle, cardiac muscle and 
adipose tissue (Becker 2001) (Figure 1). Studies have shown that accumulation of 
metabolites of fatty acids impairs Glut4 recruitment to the cell membrane in 
skeletal muscle and adipose tissue (Kim et al. 2004). Furthermore increased 
insulin secretion during the hyperinsulinemic state reduces the amount of Glut4 
receptors through a negative feedback system. 
 
Figure 1. A simplified scheme showing insulin-mediated glucose uptake into the cell. 
IR:insulin receptor, IRS-1: insulin receptor substrate 1, PI3K: phosphatidylinositol 3 
kinase, PIP2/(3): phosphatidylinositol (3),4,5-bis/(tris)phospate, Akt: Akt serine/threonine 
kinase, GLUT4: glucose transporter subtype 4. 
2.1.5 Diabetic cardiomyopathy and ventricular remodelling 
Target organ damage is the major reason for the increased risk of premature 
death, poor quality of life and the social economic burden that can be attributed to 
diabetes (Current Care guideline for diabetes, Duodecim 2009). Notorious 
complications of diabetes include damage to small blood vessels called 
microangiopathy, with target organs including the retina of the eye (retinopathy), 
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the kidney (nephropathy) and damage to cells of the peripheral nervous system 
(neuropathy). On the other hand the macrovascular complications of diabetes 
include myocardial infarction and stroke. The latest addition to the growing list of 
target organ damaged by diabetes is diabetic cardiomyopathy, i.e. the direct 
adverse effects of diabetes on the heart, or more strictly the adverse effects on 
the myocardium. However, since type 2 diabetes most is commonly accompanied 
by hypertension and dyslipidemia, it is difficult to discern the precise role of 
diabetes in the birth of these complications. Cardiovascular causes are the 
leading complications attributed to the increased mortality and morbidity in type 2 
diabetes. This study is focused on the adverse effects of diabetes on the heart. 
The heart is made up of cardiomyocytes (heart muscle cells), coronary arteries 
and veins and fibroblasts producing an extracellular matrix and electrical 
conductance fibres, which are all enveloped in the pericardial sac. The functional 
part of the myocardial apparatus is made up of cardiomyocytes that contract in 
unison to produce a rhythmic pumping effect propelling the blood through the 
arteries. As with all muscles in the body, the heart is able to adapt in the event of 
an increased perfusion demand in peripheral organs. However, maladaptive 
changes in the heart may occur in pathologic states such as diabetes, 
hypertension, ischemic heart disease or valvular disease. Ventricular remodelling 
is an adaptive process that results in reversible or irreversible changes in heart 
architecture (for a review, see Opie et al. 2006). The extent of the remodelling is 
determined by the underlying reason and may range from a physiological 
increase in stroke volume (e.g. endurance athletes) to a pathological decrease in 
stroke volume (e.g. after myocardial infarction). The term ventricular remodelling 
was first introduced in 1985 when Pfeffer and colleagues studied the effects of 
coronary artery ligation on ventricular topography in the rat myocardium (Pfeffer et 
al. 1985). Since thenthe term has commonly been used to describe the post-
infarct changes in the myocardium (Pfeffer et al. 1990). Major hallmarks in 
ventricular remodelling include increased growth of myocytes leading to LV 
hypertrophy, an increase in programmed cell death i.e. apoptosis and the build -
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up of connective tissue, i.e. fibrosis. In LV remodelling an increase in LV 
hypertrophy is associated with an inability of the heart to produce sufficient blood 
flow to compensate for the need of increased oxygen demand, i.e. capillary 
density is decreased. In the following section we shall inspect the major aspects 
of ventricular remodelling in the diabetic heart. 
For decades it was controversial whether diabetic cardiomyopathy existed 
independently from the common co-morbidities such as hypertension and 
coronary heart disease. The concept of diabetic cardiomyopathy was introduced 
in 1972 when diabetes –associated changes in the heart were first suspected 
(Rubler et al. 1972). Since then it has become increasingly evident that diabetes 
is an independent risk factor for the development of cardiac disease. In 1998 
Haffner and colleagues showed that diabetes constitutes as high a risk of 
mortality from coronary heart disease as a prior myocardial infarction (Haffner et 
al. 1998). And more recently diabetes has been shown to act as an independent 
risk for heart failure when the effects of age, weight, cholesterol, blood pressure 
and history of coronary artery disease have been considered (Bertoni et al. 2003). 
Patients with idiopathic dilated cardiomyopathy were found to be 75% more likely 
to have diabetes than age-matched controls (Poornima et al. 2006). In 2007 a 
cohort study with 62 0000 patients from 55 countries showed that 30 days and 1 
year after acute coronary syndromes (ACS: UAP/NSTEMI or STEMI) the mortality 
risk was significantly higher in diabetic patients than in non-diabetic population 
when adjusted for hypertension, smoking and any other confounding factor 
(Donahoe et al. 2007). 
Hallmark findings in diabetic cardiomyopathy include increased LV hypertrophy, 
fibrosis, diastolic and systolic dysfunction, calcium dysregulation and 
mitochondrial dysfunction together with changes in substrate utilization that lead 
to increased oxidative stress and lipotoxicity (for a review see Boudina et al. 
2010). These alterations are reflected in the multifactorial pathogenesis that 
constitutes diabetic cardiomyopathy. The following definition of diabetic 
cardiomyopathy has been proposed recently by Aneja et al. 2008: After excluding 
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other contributory causes, diabetic cardiomyopathy can be defined as the 
presence of both of the following: 1) Evidence of cardiac hypertrophy determined 
by conventional echocardiography or MRI, 2) evidence of LV diastolic dysfunction 
(with or without LV systolic dysfunction) either clinically by transmitral Doppler or 
tissue Doppler imaging, or evidence of left atrial enlargement, or subclinically by 
novel imaging techniques or provocative testing (e.g. strain and strain-rate 
imaging, or stress-imaging). 
2.1.5.1 Functional aspects 
The factors that contribute to myocardial dysfunction in diabetic cardiomyopathy 
have been identified as dysregulation of calcium homeostasis, renin-angiotensin 
system upregulation, increased oxidative stress, altered substrate metabolism 
and mitochondrial dysfunction. In type 2 diabetes it is not uncommon to find a mix 
of systolic and diastolic dysfunction (for a review, see Fang et al. 2004). However, 
the hallmark functional disturbance in diabetic cardiomyopathy is primarily 
diastolic. Diastolic dysfunction (DD) occurs when relaxation of the ventricle is 
impaired due to reduced compliance of the ventricular wall. Usually fibrosis and 
hypertrophy are underlying causative factors which are in turn caused by 
hypertension, diabetes, ischemia or a mix of these. In DD, echocardiography 
show a characteristic increase in LV end-diastolic pressure (LVEDP), increased 
isovolumetric relaxation time and doppler flow changes including a primary 
decrease in the ratio of early to late (atrial) filling (E/A) of the LV. It has been 
shown that the prevalence of DD is increased in both types of diabetes when 
other confounding factors such as coronary artery disease have been controlled 
(Shivalkar et al. 2006; Brooks et al. 2008). Systolic dysfunction in type 2 diabetes 
is normally a later manifestation occurring as a consequence of DD. However, 
with modern techniques subtle changes in systolic function can be found in 
diabetic patients with formerly isolated DD (Yu et al. 2002; Fang et al. 2005). 
Interestingly the Framingham study with 292 diabetics and 4900 non-diabetics 
showed a gender-dependency of diabetes and congestive heart failure; the 
incidence of CHF was increased 2.4 –fold in diabetic men in contrast to a 5.1 –
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fold increase in diabetic women (Kannel 1976). Animal models of diabetes have 
shown a reduction in systolic function in STZ- treated rats compared to Wistar 
(Wold et al. 2001). In one study in diabetic GK rats, diastolic dysfunction was not 
present at baseline compared to Wistar rats; however, in hypoxic conditions 
LVEDP increased significantly more in isolated hearts of GK rats compared to 
Wistar, indicating an increased susceptibility to develop DD (El-Omar et al. 2004). 
Furthermore, mitral inflow pattern was changed towards DD in a recent study 
where GK rats were fed a high sodium diet (Grönholm et al. 2005). Altered 
intracellular calcium regulation, accumulation of intracellular fatty acids and 
glycation of interstitial collagen and intracellular ryanodine receptors (RyR) have 
been associated with the development of DD in diabetes (Choi et al. 2002; Dong 
et al. 2006; Bidasee et al. 2003; Avendano et al. 1999). Furthermore, insulin –
receptor knock-out (CIRKO) mice with myocardial infarction showed a reduction in 
the protein content of the Sarco-Endoplasmic Reticulum Calcium ATPase 2 
(SERCA2) (Sena et al. 2009). A decrease in SERCA2 protein impairs relaxation 
as the protein is largely responsible for the uptake of calcium into the 
sarcoplasmic reticulum during diastole. 
2.1.5.2 The renin - angiotensin system 
The circulating renin angiotensin system (RAS) is commonly known for its role as 
a regulator of blood pressure by regulating blood vessel constriction and water 
and mineral balance. Renin is released from the kidney in response to decreased 
perfusion (i.e. low blood pressure) of the kidney in the juxtaglomerular apparatus 
(JGA) of the afferent arteriole. Renin is an enzyme that cleaves circulating 
angiotensinogen (secreted from the liver) to angiotensin I (ang I). Ang I is further 
cleaved to Ang II by angiotensin converting enzyme (ACE) mainly on the surface 
of pulmonary endothelial cells. Ang II increases systemic blood pressure (JGA 
perfusion) by 1) arteriolar vasoconstriction, 2) increasing sympathetic nervous 
system activity 3) increasing tubular Na+ and  Cl- reabsorption leading to H20 
retention alone and by stimulating aldosterone secretion from the adrenal cortex 
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and 4) by reducing ADH secretion. The effects of RAS activation on organs such 
as the heart include hypertrophy, proliferation and fibrogenesis.  
In the adult cardiovascular system Ang II induces its effects by binding to the AT1 
-receptor whereas expression of the AT2 –receptor primarily declines after birth 
(for a review, see Lavoie et al. 2003). Recently a third component of the RAS has 
been identified, namely the Ang (1-7) – Mas receptor axis. Ang (1-7) is formed 
from Ang I and Ang II by ACE2, neutral endopeptidase (NEP) and ACE and acts 
by binding to the Mas receptor (Figure 2) (Donoghue et al. 2000). Recent 
evidence suggests that at least part of the beneficial effects of ACE inhibitors in 
the heart can be attributed to the shunting of Ang I to the Ang (1-7) – Mas axis 
from the Ang I – Ang II –AT1 receptor axis (Simões e Silva et al. 2006). In many 
ways the Ang (1-7) – Mas receptor axis acts on the heart in opposition to the Ang 
II – AT1R pathway. Ang (1-7) – Mas receptor activation has been shown to be 
anti-proliferative, anti-hypertrophic and antifibrinogenic (Santos et al. 2004). 
2.1.5.2.1 The local renin angiotensin system 
The revelation of a local or tissue RAS, independent but interacting with the 
systemic RAS, was a breakthrough finding in the 1970s (Ganten et al. 1971). At 
present a local RAS has been found in several organs including the heart (Bader 
et al. 2001). Additionally, the ACE2 – Ang (1-7) - Mas –receptor axis has been 
suggested to have an important role in intracardiac RAS (Donoghue et al. 2000). 
Present data indicate that the local cardiac RAS acts to amplify the effects of the 
systemic RAS; consequently it has been shown that myocardial infarction (MI) 
increases the activity in circulating RAS and it is associated with an increase in 
intracardiac RAS (Sun 2010; Bader et al. 2008). Futhermore, angiotensin II type 1 
receptors are overexpressed after MI (Sun et al. 1994) and increased local 
production of Ang II from Ang I occurs when ACE expression is upregulated in 
endothelial cells of neovasculature, macrophages and myofibroblasts 
(Falkenhahn et al. 1995; Sun 1996). Local renin production has been shown to 
occur at the infarct site, however, there is conflict over the significance of local 
renin production and it has been proposed that activation of the local RAS starts 
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with increased uptake of angiotensinogen and renin from the circulation (Passier 
et al. 1996; Sun et al. 2001). Studies in rats have shown that the regulation of 
tissue AT1 receptor mRNA expression is independent of the circulating RAS 
(Sechi et al. 1996). 
 
Figure 2. A simplified scheme of the components and actions of the renin-angiotensin 
system. Black boxes indicate peptides/proteins, gray boxes indicate enzymes, white 
boxes indicate receptors. Ang=angiotensin, PRR=prorenin receptor, AT=angiotensin 
receptor, ACE=Angiotensin converting enzyme, AP=aminopeptidase, NEP=neutral 
endopeptidase, PCP=prolyl carboxylpeptidase. (Modified from Goodman & Gilman’s the 
pharmacological basis of therapeutics, 12th ed. 2010). 
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In diabetes, local RAS activation in the heart is believed to contribute to increased 
fibrosis, apoptosis and oxidative stress; the hallmarks of diabetic cardiomyopathy 
(Fang et al. 2004). Activation of the RAS, both local and systemic, is strongly 
associated with the development of insulin resistance and the onset of type 2 
diabetes. Indeed blocking the RAS has been shown to attenuate diabetic 
cardiomyopathy and increase insulin sensitivity and prevent the onset of type 2 
diabetes (Machackova et al. 2004; Niklason et al. 2004; Scheen 2004; Abuissa et 
al. 2005; Liu et al. 2006; Ribero-Oliveira et al. 2008 and de Kloet et al. 2010). On 
the other hand, studies with type 1 diabetic subjects have shown a decrease in 
plasma renin activity (PRA) indicating a suppressed circulating RAS in insulin 
dependent diabetes (Bojestig et al. 1999). 
Animal experiments have shown that Ang II infusion induces insulin resistance 
(Richey et al. 1999); and Mas receptor knockout mice show characteristic signs of 
the metabolic syndrome including dyslipidemia, hyperinsulinemia and obesity 
(Santos et al. 2008). Furthermore, increased levels of tissue angiotensinogen, 
Ang II and AT1 receptors have been shown in diabetic rat hearts (Khatter et al. 
1996; Fiordaliso et al. 2000). Spontaneously diabetic BB rats (insulin dependent 
DM) treated with the ACE inhibitor captopril showed amelioration of cardiac 
dysfunction and cardioprotection with decreased fibrosis (Rösen et al. 1995). 
These results provide evidence for the involvement of local RAS in diabetic 
cardiomyopathy and break ground for further research in this field. 
2.1.5.3 Left ventricular hypertrophy 
Left ventricular (LV) hypertrophy is an independent risk factor for heart failure. 
The rationale is simple: an increase in cardiac mass increases oxygen 
consumption and thereby presents an increased risk for ischemic attacks. 
Furthermore, changes in LV architecture may predispose for cardiac dysfunction. 
Numerous studies have shown that patients with type 2 diabetes have an 
increase in LV hypertrophy independent of other confounding factors including 
hypertension (Galderisi et al. 1991; Devereux et al. 2000; Eguchi et al. 2008). 
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Hypertrophy is a form of growth which is characterized by an increase in average 
cell size of the constituting organ (in contrast to hyperplasia where the number of 
cells increases). Although left ventricular hypertrophy is more common, the right 
ventricle can also become enlarged or both may be affected. The common factor 
is that in physiological cardiac hypertrophy the intermittent load induces an 
increase in chamber wall thickness; this is compensated by an increase in 
ventricular volume, thus balancing wall thickness to chamber volume ratio (Dorn 
2007). In pathological hypertrophy the chronic pressure or volume load imposed 
on the heart due to e.g. a stenotic valve or hypertension promotes the 
pathological changes in wall structure. The three major patterns of ventricular 
hypertrophy are divided into the following: 1) concentric left ventricular 
hypertrophy, 2) eccentric left ventricular hypertrophy and 3) mixed post-infarct 
hypertrophy (Figure 3). In chronic hypertension, concentric hypertrophy develops 
in response to increased peripheral resistance, this is known as afterload. 
Echocardiography suggests that obesity per se and diabetes are associated with 
mainly concentric but also eccentric LV hypertophy (Woodwiss et al. 2008; Ojji et 
al. 2009); since hypertension is a common co-morbidity in diabetes, concentric 
hypertrophy is expected to be far more common. 
In type 2 diabetes LV hypertrophy may not be present in the early stages and 
instead may manifest after a longer period. The mechanisms that contribute to LV 
hypertrophy in diabetes are not entirely clear. Recently however, clinical and 
animal studies have proposed evidence that an increase in circulating leptin and 
resistin from adipose tissue can induce concentric LV hypertrophy (Barouch et al. 
2003; Eguchi et al. 2008). Hyperinsulinaemia in early type 2 diabetes has been 
linked to LV hypertrophy (Karason et al. 2003) and insulin resistance has been 
shown to be an independent risk factor for CHF in elderly men (Ingelsson et al. 
2005). The obvious question that arises from this notion is whether insulin 
sensitivity can be preserved in some organs while resistance has developed in 
others. It has been postulated that the distribution and severity of insulin 
resistance is not uniform in all tissue types; while skeletal muscle and adipose 
26 
 
tissue are insulin resistant, insulin sensitivity may be preserved in the 
myocardium. This notion would make a logical explanation for the LV hypertrophy 
commonly seen in type 2 diabetes (for a review, see Poornima et al. 2006). 
Acutely, insulin sensitive tissue responds to insulin receptor activation by 
increasing LV hypertrophy. This is mediated by PI3K/Akt –guided increase in 
glucose uptake, GSK3-beta –guided increase in transcription of prohypertrophic 
genes and activation of mTOR –guided increase in protein synthesis (Shioi et al. 
2002; Dorn et al. 2004). However, in chronic hyperinsulinemia, desensitization of 
insulin receptor and mitochondrial Akt sequestration leads to alternative Akt –
independent pathways becoming increasingly important. Akt –independent 
pathways that have been shown to induce hypertrophy in insulin resistant tissue 
include the ERK1/2 and p38 MAPK pathways (Dobrin et al. 2010). 
 
 
Figure 3. Three major patterns of ventricular hypertrophy with examples of clinical 
situations contributing to each pattern. In all types interstitial fibrosis is accelerated (Opie 
et al. 2006). 
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2.1.5.4 Changes in energy metabolism 
The normal adult heart can use glucose and/or free fatty acids as sources of 
energy and the switch occurs smoothly depending on momentary supply and 
demand (Neely et al. 1972). In diabetes, myocardial tissue switches substrate 
utilization from a mix of fatty acids and glucose to the exclusive use of fatty acids 
(for a review, see Feuvray et al. 2008). Dysregulated lipid metabolism in the heart 
has been implicated as one of the key triggers of diabetic cardiomyopathy (for a 
review, see Dobrin et al. 2010). Peroxisome proliferator-activated receptors 
(PPARs) are transcription factors implicated in fatty acid (FA) metabolism. In 
diabetes the high utilization of FAs increase the expression of PPARs and their 
role in energy metabolism become more important. The overexpression of the 
PPAR subtype alpha (PPARalpha), the most abundant isoform of the PPARs, is 
implicated in the advent of diabetic cardiomyopathy (Finck et al. 2002). 
Experiments have shown that in the cardiomyocyte, an increase in intracellular 
fatty acids upregulates the expression of PPARalpha. However, in later stages of 
diabetes the expression of PPARalpha is downregulated and PPARgamma 
upregulated (for a review, see Saunders et al. 2008). Nuclear receptor PPAR-
gamma increases the intake of glucose into peripheral tissues via the GLUT4 
glucose transporter and reduces the free fatty acid concentration. This is an 
important target of the thiazolidinediones (glitazones), which are are medicines 
used for the management of type 2 diabetes and sensitize liver, fat and skeletal 
muscle tissue towards the actions of insulin. 
2.1.5.5 Insulin PI3K/Akt – FOXO3a pathway 
When insulin binds the insulin receptor (IR, a transmembrane receptor tyrosine 
kinase (RTK)) which initiates a number of intracellular protein activation cascades 
that have the following effects: 1) glucose transport into the cell by recruitment of 
the glucose transporter Glut-4 membrane protein 2) glycolysis and following ATP 
synthesis 3) glycogen synthesis, i.e. storage of glucose 4) fatty acid synthesis 
from glucose and pyruvate 5) protein synthesis 6) survival by inhibition of 
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proapoptotic factors. IR-activation phosphorylates PI3 kinase (PI3K) which in turn 
phosphorylates PIP2 to produce PIP3. This enables PIP3 to bind and activate the 
serine/threonine kinase Akt (Figure 1). The phosphorylation and activation of the 
PI3K/Akt pathway is counteracted by the phosphatase and tensin homologue 
PTEN which dephosphorylates PIP3 which consequently leads to 
dephosphorylation of Akt (Figure 4). 
Insulin is a well known anabolic hormone and the role of Akt as a growth 
promoting factor has been thoroughly investigated. An increase in insulin 
signalling in the heart has been shown to increase cardiac mass (Belke et al. 
2002). This notion has triggered the theory that onset of LV hypertrophy in type 2 
diabetes starts in the hyperinsulinemic state when insulin acts as a growth 
stimulus in non-insulin resistant tissue through the PI3K/Akt pathway. Recent 
studies have shown that pathological growth is associated with additional 
recruitment of signalling pathways that crosstalk with PI3K/Akt such as the 
Gq/phospholipase C (for a review, see Dorn et al. 2005). Activation of the PI3K - 
Akt pathway has been shown to increase hypertrophy through activation of the 
mammalian target of rapamycin (mTOR) (Shioi et al. 2002). Akt mediates its anti-
apoptotic effects partly by inhibiting the forkhead class O transcription factors 
(FOXOs) (Brunet et al. 1999). The FOXO family of transcription factors is an 
important group that modulates expression of genes involved in apoptosis 
(Bcl2ll11, FasL), repair of damaged DNA (GADD45), arrest of the cell cycle (p27, 
cyclins), and detoxification of ROS (SOD2) (for a review, see Huang et al. 2007). 
FOXO proteins are tightly regulated, they are activated by cJun N-terminal kinase 
(JNK) and Mammalian sterile 20-like kinase 1 (MST1), they undergo inhibitory 
phosphorylation by the Akt kinase and their actions are counterbalanced by 
deacetylation by the Sirtuin (silent mating type information regulation 2 homolog) 
1 (Sirt1)  (Huang et al. 2007). Evidence for Akt-mediated inhibition of FOXO was 
found when insulin and insulin like growth factor (IGF-1) suppressed FOXO 
activity (Ogg et al. 1996; Kimura et al. 1997). FOXO3a is a target of the insulin 
receptor - PI3K/Akt signalling pathway in cardiomyocytes and it mediates the 
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response to oxidative stress; FOXO3a phosphorylation by IR – Akt/PI3K 
inactivates expression of proapoptotic target genes such as Bcl-like 11 (Bim) and 
FasL (Franke et al. 1997). On the other hand, reduced insulin signalling reduces 
Akt/PI3K mediated –phosphorylation and thus inactivation of proapoptotic 
FOXO3a. In spontaneously diabetic Goto-Kakizaki (GK) rats, a model of type 2 
diabetes, IR – PI3K/Akt signalling and insulin dependent glucose uptake is defect 
partly due to depletion of IR subunit beta, IRS-1 and Glut4 (Galli et al. 1999; 
Desrios et al. 2004) and therefore disturbance in Akt/PI3K mediated FOXO3a –
signalling is likely to be present in the GK rat. However this has neither been 
investigated nor reported in the literature. Akt –mediated FOXO –phosphorylation 
translocates the FOXOs to the nucleus where they are sequestered to 14-3-3 
chaperones.  
 
 
Figure 4. A simplified scheme showing the major effects of insulin - PI3K/Akt pathway.  
IR: Insulin receptor, P:phosphate group, PI3K:phosphoinositide 3-kinase, 
PIP2(/3):phosphatidylinositol (3),4,5-bis(tris)phosphate, PTEN:phosphatase and tensin 
homologue 10, mTOR:mammalian target of rapamycin, p27Kip:p27 cyclin dependent 
kinase inhibitor, GSK3beta:glycogen synthase kinase 3 beta, FOXO:forkhead class O 
transcription factor.  
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2.1.5.6 Sirt1 signalling - FOXO3a and p53 
Mammalian Sirtuin1 (Sirt1) is a nuclear class III histone deacetylase enzyme 
(HDAC) with sequence homology to yeast silent information regulator 2 (Sir2) and 
it is implicated in increased longevity through suppression of DNA transcription 
(histone deacetylase effect) and through its negative actions on proapoptotic 
factors. For an overview of the regulation and organ-specific effects of Sirt1, refer 
to figure 5. In the heart Sirt1 is associated with increased cellular stress 
resistance, decreased senescence and increased hypertophy. Sirt1 is activated 
by caloric restriction and it is one of the key factors that contribute to the 
increased life span associated with reduced energy intake (Lin et al. 2000; Howitz 
et al. 2003). As expected, recent studies have provided a connection between 
Sirt1 –mediated cell survival and the PI3K/Akt –pathway (for a review see 
Sundaresan et al. 2011). Phosphorylation of cytoplasmic Sirt1 by the Akt kinase 
promotes nuclear translocation of Sirt1 (Tanno et al. 2010). In the nucleus Sirt1 
inactivates transcription of genes implicated in reduced longevity (maintenance of 
intact telomeres) and apoptosis such as p53 and FOXO3a. Sirt1 –mediated 
deacetylation is coupled to nicotinamide adenine dinucleotide (NAD+) hydrolysis 
which yields the deacetylated substrate and nicotinamide (NAM). NAD+ is  a  
coenzyme implicated in the energy transfer chain by accepting electrons 
(becoming the reduced form: NADH) and donating them (returing to the oxidized 
state NAD+). Hence, Sirt1 activity is sensitive to the oxidative state of the cell, a 
high NAD+/NADH –ratio increases Sirt1 activity and nicotinamide functions as a 
feedback inhibitor (for a review, see Shore 2000). Gene expression of Sirt1 is 
regulated by numerous transcription factors. Negative feedback loops are 
provided by p53, HIC1 and FOXO3 (Yamakuchi et al. 2009).  In the 
posttranslational setting Sirt1 activity and localisation is modulated not only by 
NAD and PI3K/Akt, but also by direct protein binding and small molecule 
activation. The main proteins that modifiy Sirt1 activity include the activator 
protein active regulator of Sirt1 (AROS) and the negative regulator deleted in 
breast cancer 1 (DBC1) (for a review, see Haigis et al. 2010). Exogenous small 
31
molecule modulators of Sirt1 include activators such as the polyphenol resveratrol 
and inhibitors such as sirtinol. Resveratrol binds Sirt1 at the same N-terminal site 
as AROS and DBC1.  
Figure 5. Sirt1 and its organ-specific effects: Sirt1 increases life span and is a key 
regulator of cellular energy metabolism. The level of Sirt1 protein, NAD, Sirt1-
phosphorylation, AROS and resveratrol are positive modulators of Sirt1; whereas DBC1 
and sirtinol are negative regulators of Sirt1. LVH=left ventricular hypertrophy, FA=Fatty 
acid, NAD=nicotinamide dinucleotide, AROS=active regulator of Sirt1, DBC1=deleted in 
breast cancer 1. (Modified from Haigis et al. 2010). 
Hyperglycemia-induced ROS and RNS build-up has been implicated in an 
increase in p53 –and Caspase -3 dependent cardiomyocyte apoptosis in human 
diabetes and in animal models (Frustaci et al. 2000; Fiordaliso et al. 2001). 
Furthermore, the tumor suppressor and transcription factor p53 is implicated in 
increased cardiomyocyte apoptosis in response to oxidative stress, hypoxia, 
stretch and DNA damage (for reviews, see Von Harsdorf et al. 1999 and Giordano 
2005). In response to cellular stress, p53 is maintained at a relative high level by 
post-translational modifications including phosphorylation and acetylation. It has 
been shown that the lysine acetylation at the site K373/K382 is linked to the ability 
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of p53 to regulate cell cycle arrest and apoptosis (Zhao et al. 2006). The anti-
apoptotic effects of Sirt1 are in part mediated through deacetylation of p53 at 
K373/382 (Luo et al. 2001). Sirt1 modulates the activity of FOXO3a, a 
transcriptional regulator and member of the forkhead class O (FOXO) family. 
Nuclear FOXO3a is subject to acetylation by CBP and p300 and FOXO3a –
acetylation is increased in response to oxidative stress (Huang et al. 2007). 
Accordingly Sirt1 modulates FOXO3a transcriptional activity to favour of cell 
survival. Deacetylation of FOXO3a inhibits transcription of apoptotic genes, 
increases transcription of genes implicated in cell cycle arrest and increases 
transcription of genes associated with resistance to oxidative stress (Brunet et al. 
2004). In rat and dog hearts, the Sirt1 protein has been shown to inhibit apoptosis 
and act as a pro-hypertrophic factor (Alcendor et al. 2004; Alcendor et al. 2007). A 
role for Sirt1 in alleviating insulin resistance was suggested when Sirt1 activation 
increased insulin sensitivity through activation of the peroxisome proliferator-
activated receptor gamma coactivator-alpha (PGC1alpha) (Lagouge et al. 2006). 
Sirt1 is a key regulator of energy and metabolic homeostasis, and since diabetes 
is associated with disturbance in these, the role of Sirt1 in the development of 
diabetic cardiomyopathy is intriguing and should be further investigated. 
2.1.5.7 P38 Mitogen activated protein kinase 
In the heart, the mitogen activated protein kinase (MAPK) signalling system 
represent an important mechanism for cellular stress response (for a review, see 
Rose et al. 2010). The four most thoroughly investigated MAPK:s include ERK1/2, 
ERK5, JNK and p38. Recent information provides an important role for p38 MAPK 
activation in insulin resistance (Henriksen et al. 2010). Mitogen activated protein 
kinase (MAPK) p38 is activated by angiotensin II, inflammation, oxidative stress 
and ischemia (Gao et al. 2002; Zhang et al. 2004). Intracellular factors such as 
DNA damage or extracellular factors such as binding of proapoptotic FasL induce 
protein kinase cascade activation (MEKK1-4, MLK, MKK) and subsequent p38 
MAPK activation. Previous studies suggest that p38 MAPK activation reduces 
contractility (Liao et al. 2002). In experimental MI, inhibition of p38 MAPK has 
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been shown to reduce ventricular remodelling (See et al. 2004). Long-term, but 
not short-term activation of the p38 MAPK is deleterious as it increases fibrosis, 
hypertrophy and apoptosis (Kompa AR. 2008). Previous studies have shown that 
p38 induces collagen formation, CTGF mRNA expression and proinflammatory 
cytokine IL-6 in the heart (Tenhunen et al. 2006). The role of p38 MAPK has not 
been studied in detail in diabetic GK rat hearts. For a review of p38 and its effects 
on gene expression in spontaneously hypertensive rats with LVH, see (Rysä 
2009).  
2.1.5.8 Cardiomyocyte renewal and senescence 
The ageing heart evokes the typical clinical symptoms resulting from a decline in 
cardiac function. Until a decade ago it was thought that hypertrophy is the only 
means of growth in the heart. However, breakthroughs in imaging and the 
discovery of markers of cellular proliferation have provided evidence that dividing 
myocytes are present in the non-diseased heart and that proliferation of 
cardiomyocytes is accelerated in the infarct border zone (for a review, see 
Anversa et al. 2002). A recent study showed that annual cardiomyocyte turnover 
occurs at an age-dependent pace ranging from 1% to 0.5% in the human heart 
(Bergmann et al. 2009). The exact role of the recently discovered resident cardiac 
stem and progenitor cells (CSC) is currently unclear (for a review, see Torella et 
al. 2008). The revelation of resident cardiac stem cells has sparked the design of 
novel therapies for the treatment of myocardial infarction, including the 
implantation of progenitor cell sheets in the infracted area.  
When stem cells age they lose their restorative capacity. In an aging organism, 
cells lose their functional abilities, cease to grow and replicate, and ultimately 
undergo apoptosis, a process called cellular senescence. Age-dependent 
increases in specific tumour suppressor proteins have been recently discovered; 
these markers of senescence have been shown to promote apoptosis by 
activating key apoptotic factors such as p53 (see section on apoptosis above). 
Two essential markers of cellular senescence in the cardiomyocyte include 
p16INK4a and p19ARF (for a review, see Sharpless 2004). 
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2.1.5.9 Programmed cell death (Apoptosis) 
Apoptosis or programmed cell death is an important process during development 
in all organisms. Apoptosis is a tightly regulated process where cells go through 
the characteristic steps of DNA fragmentation, chromatin condensation, nuclear 
shrinking and formation of apoptotic bodies. Later in life, apoptosis is used to 
dispose of cells that are old or have been injured; however apoptosis can be 
harmful if it is unintentional or occurs in excess. In the heart, programmed cell 
death has been recognised as an important process in the progression to heart 
failure (for a review, see van Empel 2005). A cell can undergo apoptosis via either 
the extrinsic or intrinsic pathways or via a combination of the two. Activation of the 
extrinsic pathway is initiated by extracellular stimuli such as toxins, hormones or 
growth factors and involves the binding of one of the death ligands TNF-alpha, 
FasL or TRAIL to receptors of the TNFR family. Ligand-receptor binding results in 
the formation of a death inducing signalling complex (DISC). Intra- or extracellular 
stress factors such as hypoxia, ischemia/reperfusion, oxidative stress or 
increased intracellular calcium concentration activates the intrinsic pathway. The 
intrinsic pathway involves proteins located in the ER and the mitochondria, 
including Bcl2 and cytochrome C and the effector caspases.  
In animal models for obesity and diabetes an increase in apoptosis has been 
shown to occur in the heart (Barouch et al. 2006). Several mechanisms have 
been proposed to lead to the increase in apopotic cell death; these include gluco- 
and lipotoxicity, mitochondrial dysfunction and activation of the RAS. All of these 
lead to an increase in the build-up of reactive oxygen species (ROS). The high 
circulating and intracellular stores of fatty acids leads to alternative non-oxidative 
forms of energy production that result in the accumulation of toxic by-products. 
The reactive lipids react with oxygen products to produce toxic reactive lipid 
species that may lead to increased cell death (Dorn 2009). 
Mitochondrial dysfunction in diabetes has been widely recognised as a contributor 
for diabetic cardiomyopathy and a source for excessive ROS build-up (Boudina et 
al. 2006). Indeed, diabetes, ROS build-up and hyperglycemia have been 
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implicated in p53- and caspase 3- dependent increase in cardiomyocyte 
apoptosis (Cai et al. 2001; Fiordaliso et al. 2001; Giordano et al. 2005). 
Furthermore, increased RAS activity in the diabetic heart has been associated 
with increased apoptosis (Frustaci et al. 2000). 
2.1.5.10 Fibrosis 
In cardiac fibrosis the increased production and deposition of collagen and other 
extracellular matrix proteins leads to stiffening and reduced relaxation of the 
ventricles. The echocardiographic features of increased LV fibrosis appear as 
impaired relaxation and diastolic dysfunction (increased LVEDP and primary 
decrease in E/A ratio). Typically, fibrosis is a highly regulated protective 
mechanism that restores the general architecture of the parenchyma. For 
example, after MI interstitial fibrosis occurs at the infarct site to produce the scar 
and continues somewhat in the border zone; being non-functional this contributes 
to myocardial stiffness and development of cardiac dysfunction. In diabetic 
cardiomyopathy increased collagen deposition and fibrosis are considered 
hallmark histological features (Regan et al. 1977; Frustaci et al. 2000). Consistent 
with this, it has been proposed that a modest increase in interstitial fibrosis is the 
initial cue for diabetic cardiomyopathy (Shimizu et al. 1993). In a study with 
prediabetic OLETF rats there was a correlation between increased extracellular 
collagen content and a decrease in early mitral peak flow (decreased E/A ratio) 
(Mizushige et al. 2000). The cause for increased collagen accumulation in 
diabetes is believed to result from 1) reduced degradation of glycosylated 
collagen and 2) increased production due to increased RAS activation (for a 
review, see Fang et al. 2004). 
2.1.6 Ischemic heart disease and heart failure 
Subjects with type 2 diabetes are at a higher risk for developing atherosclerosis 
and ischemic heart disease including fatal myocardial infarction (Haffner et al. 
1998). Recent evidence has shown that diabetes and prior MI are equal risk 
factors for mortality following acute coronary syndromes (including unstable 
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angina pectoris (UAP), non-ST elevation myocardial infarct (NSTEMI) and ST-
elevation myocardial infarct (STEMI)) (Donahoe et al. 2007). Several mechanisms 
have been proposed that contribute to the increased atherogenesis including 
increased production of reactive oxygen species (ROS), altered substrate 
metabolism and dyslipidaemia (for a review, see Fang et al. 2004). In the 
coronary arteries, diabetes is associated with endothelial dysfunction, whereas 
the myocardium is afflicted by a mixture of insulin resistance and increased RAS 
activation, which further accelerates the atherogenesis. Hypertension is a risk 
factor for ischemic heart disease and type 2 diabetic patients’ blood pressure 
values should be kept at below 130/80 mmHg due to the aggregate effect of 
diabetes and hypertension on the development of coronary heart disease.  
Atherogenesis in the medial layer of the coronary arteries may result in the 
formation of a fibroatheroma. Fibroatheromas can be classified into lipid-rich 
plaques that risk rupture and embolisation or fibrotic ones that are more likely to 
undergo thrombosis, both of which are risks for myocardial infarction (MI). MI in 
the left ventricle results from occlusion somewhere in the left coronary artery 
(LCA). Occlusion in the left anterior descending (LAD) artery results in cessation 
of blood flow to the anterior wall and septum of left ventricle. An established 
method for inducing experimental MI with following post-MI heart failure in 
experimental animals is to ligate the LAD coronary artery. Complications of 
myocardial infarction include sudden cardiac death, hypertrophy, fibrosis, rupture 
of the chordae, and ischemia of the papillary muscle, valvular disease, ventricular 
aneurysms, septum perforation, pericardial tamponade, and post-MI arrhythmia. If 
reperfusion does not occur within hours, the hypoxic area undergoes 
inflammation, apoptosis, necrosis and fibrosis. The non-infarct area undergoes 
architectural changes to compensate for the loss in function. In the long-term the 
non-functional scar tissue, the change in architecture of viable tissue together with 
potential post-MI complications together contribute to the development of heart 
failure. 
37 
 
2.1.7 Rodent models of diabetes 
Type 2 diabetes is a multifactorial disease and both environmental and congenital 
factors are involved in the pathogenesis; hence there are no animal models that 
specifically mimic human type 2 diabetes. Although inadequate to fully replicate 
the clinical situation, the following rodent models have proven useful for studying 
hyperglycaemia, insulin resistance and the development of cardiomyopathy (for a 
review, see Bugger et al. 2009) (table 2). 
2.1.7.1 The Goto-Kakizaki rat 
The Goto-Kakizaki (GK) rat was developed by selective inbreeding of glucose 
intolerant Wistar rats (Goto et al. 1976). Chromosomal mapping of the genetic 
defects in the GK rats has revealed 6 independent loci involving mutations 
(Gaugier et al. 1996). Already at a few weeks of age the GK rats exhibit mild 
hyperglycemia, hyperinsulinaemia, glucose intolerance and peripheral insulin 
resistance (Bisbis et al. 1993). The GK rat heart has been shown to be partly 
insulin resistant. Insulin resistance in the GK rat heart is associated with a 31% 
reduction in insulin receptor protein expression and 38% reduction in IRS-1 
protein expression. This is associated with 37% and 45% decrease in insulin –
stimulated phosphorylation of these proteins, respectively (Desrois et al. 2004). 
An increased susceptibility to oxidative stress has been shown in various studies. 
ROS build-up due to hyperglycemia and increased FFA, mitochondrial 
dysfunction and reduced levels of antioxidant has been proposed to play a crucial 
role in the pathogenesis in GK rats (Santos et al. 2003; Bitar et al. 2005). Our 
studies have shown that GK rats develop endothelial dysfunction, left ventricular 
hypertrophy, moderate hypertension and are salt-sensitive. The involvement of 
RAS activation in the pathogenesis is supported by the beneficial effects of ang II 
inhibition in GK rats fed with a high salt diet (Cheng et al. 2004). 
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Table 2. Rodent models of diabetes and obesity 
 Type 1 diabetes Obesity/Type 2 diabetes 
Model STZ OEV26 
mouse 
Akita mouse DIO mouse ob/ob 
mouse 
db/db 
mouse 
ZDF rat GK rat 
Mechanism 
in brief 
Stretpto-
zotocin 
induced beta 
cell loss 
Calmodulin 
overxpres-
sion induced 
beta cell 
loss 
Ins2 gene 
mutation –
misfolding of 
proinsulin and 
beta cell failure 
Diet –
induced 
obesity 
model. High 
fat diet. 
Ob gene 
mutation, 
leptin 
deficiency, 
loss of 
appetite 
suppression 
Leptin 
receptor 
defect, 
loss of 
appetite 
suppressi
on 
Inbred 
hyperglyc
aemic 
ZFR with 
Lepr 
mutation 
Inbred 
from 
glucose 
intolerant 
Wistar rats 
Background 
strain 
Any FVB C57BL/6 C57BL/6 C57BL/6 C57BL/K 13M Wistar 
Latency to 
diabetes 
1-2 weeks 
after injection 
1 week 
postpartum 
5-6 weeks 
postpartum 
Mature 15 weeks 
postpartum 
8 weeks 
postpartu
m 
6-12 
weeks 
postpartu
m 
4-8 weeks 
postpartu
m 
Obese/non-
obese 
Non-obese Non-obese Non-obese Obese Obese Obese Obese Non-
obese 
LV 
hypertrophy 
? N/A N/A ? ? ? ? ? 
Cardiac 
function 
? ? ? N/A ??? ? ? ??? 
STZ: Streptozotocin, ZDF: Zucker diabetic fatty, ZFR: Zucker fatty rat, GK: Goto-Kakizaki
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2.2 Levosimendan 
2.2.1 Pharmacological properties and dosing 
Levosimendan, or (-) (R)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-
pyridazinyl)phenyl]hydrazono]-propanedinitrile has a molecular weight of 280.291 
g/mol and the molecular formula is C14H12N6O. Levosimendan is commercially 
available as 1 ml, 5 ml and 10 ml ampoules with 2.5 mg/ml concentrate for 
intravenous infusion. The dose and duration of infusion varies on an individual 
basis and with the dose being based on the clinical situation and response to 
treatment. Usually infusion in a peripheral or central vein starts with a 10 minute 
bolus of 6-12 µg/kg and the treatment continues at a rate of 0.1 µg/kg/min. The 
recommended total infusion duration is 24 hours for patients with severe 
decompensated congestive heart failure. 
 
 
Figure 6. Chemical structure of levosimendan 
2.2.2 Pharmacokinetics 
Approximately 97% of levosimendan is bound to plasma proteins, mainly albumin. 
Levosimendan is metabolized by conjugation to cyclic or acetylated cystein 
(Lehtonen et al 2004). Levosimendan is excreted into the intestine where bacterial 
metabolism yields the active circulating metabolites OR-1855 and OR-1896. The 
half-life of elimination for levosimendan is one hour. The metabolites appear 
slowly in the circulation, ca. 2 days after cessation of infusion. The half lives of 
OR-1855 and OR-1896 are longer, between 75 to 80 hours. The haemodynamic 
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effects of levosimendan infusion are a combination of the acute effects 
(levosimendan) and long-lasting effects (OR-1896). When levosimendan was 
given to rats in drinking fluid at a concentration of 10 mg/l, the average daily dose 
calculated from weekly plasma samples over a 7-week period averaged 3.6 
mg/kg (Louhelainen et al. 2007). In the same set-up, the mean 24 –hour plasma 
concentrations of levosimendan and its metabolite OR-1896 were 79 ± 19 ng/ml 
and 42 ± 15 ng/ml respectively. 
2.2.3 Pharmacodynamics and mechanisms of action 
The myocardial contractile apparatus includes the myofilaments actin and myosin 
and a complex of interacting regulatory proteins namely tropomyosin and the 
troponins T (TnT), I (TnI) and C (TnC). When calcium attaches to troponin C it 
causes a conformational change in the complex allowing the formation of cross 
bridges between actin and myosin, i.e. contraction occurs. Levosimendan 
increases calcium sensitivity of contractile proteins in the cardiomyocyte by 
binding to TnC. Levosimendan stabilizes TnC and does not increase intracellular 
calcium concentration (Pollesello et al. 1994). In the failing heart levosimendan 
acts as a positive inotrope, i.e. it increases the strength of contraction. Diastolic 
function is preserved due to the rapid detachment of levosimendan from TnC 
during relaxation (Levijoki et al. 2000; Antoniades et al. 2007); additionally 
levosimendan has been shown to enhance diastolic function in paced dogs 
(Tachibana et al. 2005). 
In addition to acting as a positive inotrope, levosimendan exerts vasodilatory 
effects. This is mediated mainly through opening of ATP –dependent potassium 
(KATP) –channels in small resistance vessels of arterial vasculature leading to 
outflow of potassium and subsequent hyperpolarization of the membrane potential 
(Yokoshiki et al. 1997). Levosimendan has also been shown to activate voltage –
sensitive and calcium –activated potassium channels (BKCa) (Pataricza et al. 
2003). Furthermore, levosimendan has been shown to act as a 
phosphodiesterase 3 –inhibitor (Gruhn et al. 1998). Inhibition of PDE3 increases 
the amount of second messenger cAMP which on the one hand activates calcium 
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influx in the cardiomyocyte and thus increase force of contraction and on the other 
hand induce vasodilation by outflux of calcium. However, the clinical relevance of 
levosimendan’s PDE3 inhibitory effect remains unclear. The active metabolite 
OR-1896 activates KATP and  BKCa –channels and its vasodilatory effects are 
comparable to levosimendan (Erdei et al. 2006).  
Prior studies suggest that levosimendan has beneficial effects on myocardial 
ischemia, apoptosis and inflammation that are independent of its inodilatory 
effects (Parissis et al. 2004; Adamopoulos et al. 2006). It has been postulated that 
by opening mitochondrial ATP –dependent potassium channels (mKATP), 
levosimendan may exert anti-ischemic effects that mimic preconditioning (Kersten 
et al. 2000; Kopustinskiene et al. 2004). In the energy deprivation state such as 
ischemia, opening of the mitoKATP –channels in the cardiomyocyte has been 
suggested to maintain mitochondrial matrix volume and preserve sufficient energy 
transfer upon reperfusion (for a review, see Garlid et al. 2003). The anti-apoptotic 
effects have been speculated to be due to the potassium channel opening 
properties (Louhelainen et al. 2007). The clinical relevance of the anti-apoptotic 
and anti-inflammatory properties are still unclear. The beneficial effects on 
ventricular remodelling described here provided a basis to study the effects of 
levosimendan in a rodent model of diabetic cardiomyopathy with post-MI heart 
failure. 
2.2.4 Experimental studies 
Levosimendan has been investigated in several animal models. A recent study 
examined levosimendan, milrinone and dobutamine in anaesthetized dogs and 
confirmed that levosimendan acts as an inodilator and does not increase 
myocardial oxygen consumption in contrast to the other compounds (Banfor et al. 
2008). In isolated rabbit hearts, pre-treatment with levosimendan prior to 
ischemia-reperfusion was shown to have a positive effect on recovery (Leprán et 
al. 2006). In porcine models levosimendan has been shown to increase success 
rate after cardiopulmonary resuscitation (Koudona et al. 2007) and to partly 
restore right ventricular function after pulmonary embolism (Kerbaul et al. 2007) 
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compared with placebo treatments. The effects of levosimendan on endotoxaemia 
has been studied in sheep (Dubin et al. 2006), and further studies have been 
performed in the guinea pigs (Kaheinen et al. 2004), rats (Louhelainen et al. 2007; 
Boost et al. 2008) and dogs (Banfor et al. 2008).   
2.2.5 Clinical use 
Levosimendan is the only calcium sensitizer presently used and it is prescribed 
for the management of acute decompensated heart failure (ADHF). 
Levosimendan is used “off-label” for other cardiovascular disorders such as 
cardiogenic shock, septic shock and as perioperative cardiac support. In contrast 
to other positive inotropes, levosimendan has been suggested to exert its effects 
without increasing oxygen demand (Ukkonen et al. 1997). And furthermore, 
studies suggest that levosimendan does not increase intracellular calcium 
concentration and does not activate the sympathetic system (for a review see 
Antila et al. 2007). Its beneficial effects on heart failure (HF) symptoms include 
reduced dyspnoea and decreased P-BNP. The use of levosimendan for ADHF is 
associated with shorter hospital stays compared to dobutamine (Mebazaa et al. 
2005).  
2.2.5.1 Clinical trials 
In clinical trials the effects of levosimendan on heart failure symptoms have been 
beneficial, whereas the effects on mortality have yielded controversial results. In 
three clinical trials levosimendan was proven to be superior to dobutamine (LIDO, 
203 patients), to placebo (RUSSLAN, 504 patients) and both (CASINO, 299 
patients) (Follath et al. 2002; Moiseyev et al. 2002; Lehtonen et al. 2007) In two 
recently finished large clinical trials levosimendan did not improve mortality 
compared to placebo (SURVIVE, 1327 patients) and dobutamine (REVIVE II, 600 
patients) (Lehtonen et al. 2007; Mebaaza et al. 2007). In one clinical trial 1 mg 
levosimendan was given orally once or twice a day (PERSIST, 307 patients) and 
compared with placebo treatments in randomly assigned HF patients with NYHA 
IIIB-IV symptoms. Levosimendan improved the quality of life score (Minnesota 
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living with heart failure quality of life score) and reduced the plasma concentration 
of NT-ProBNP but did not affect the primary composite end-point consisting of 
repeated symptom assessments, worsening of heart failure and mortality during 
60 days (Nieminen et al. 2008). 
2.2.6 Adverse effects 
Levosimendan is well tolerated in general; however some adverse events mainly 
affecting the cardiovascular system are associated with the use of levosimendan. 
Hypotension is classed as a very common adverse event (occurring in ?1/10 
subjects), whereas common adverse events affecting the heart include atrial 
fibrillation, tachycardia, heart failure, cardiac ischemia and extrasystole (occurring 
in ?1/100 subjects). In the gastrointestinal system nausea, constipation, 
diarrhoea, vomiting are commonly occurring adverse events. Other common or 
very common adverse events include hypokalemia, insomnia, headache, vertigo 
and decrease in blood haemoglobin. 
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3 Aims of the study 
Diabetes is an independent risk factor for the development of left ventricular 
hypertrophy, diastolic dysfunction and myocardial infarction. The increasing 
prevalence demands for better understanding of the molecular mechanisms that 
contribute to cardiac remodelling. The aim of this study was firstly to characterize 
the molecular mechanisms of diabetic cardiomyopathy in spontaneously diabetic 
Goto-Kakizaki (GK) rats. Secondly, we aimed to examine the effects of 
myocardial infarction (MI) on ventricular remodelling in diabetic GK rats. Thirdly, 
the aim was to study the effects of the calcium sensitizer levosimendan on post-
infarct heart failure and left ventricular remodelling. 
For these goals the following specific aims were established: 
 
I. To investigate whether left ventricular remodelling is associated with cardiac 
dysfunction, apoptosis, left ventricular hypertrophy and fibrosis in diabetic GK 
rats. And to examine whether longevity-associated and pro-hypertrophy pathways 
Sirt1 – p53 and - FOXO3a are altered in the myocardium of GK rats. 
 
II. To examine the effect of myocardial infarction on the parameters of left 
ventricular remodelling stated in aim I, and to further study the role of Akt - 
FOXO3a, Sirt1 - p53 signalling pathways in the pathogenesis. 
 
III. To examine the effects of oral levosimendan treatment on 1) post-MI left 
ventricular remodelling and 2) myocardial gene expression profile in the diabetic 
GK rat. 
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4 Materials and methods 
4.1 Experimental animals 
4.1.1 Spontaneously diabetic Goto-Kakizaki rats 
The Goto-Kakizaki rat is a model of type 2 diabetes developed by selective 
inbreeding of glucose intolerant Wistar rats (Goto et al 1976). The GK rats are 
non-obese and develop mild hyperglycemia at 4-8 weeks (fP-Gluc up to 8 
mMol/L), modest hyperinsulinemia, glucose intolerance, impaired glucose-
induced insulin secretion and peripheral insulin resistance spontaneously. The GK 
rats are further dyslipidemic and show a degree of coagulation disorder. The GK 
rats develop modest hypertension and cardiac hypertrophy spontaneously, and 
GK rats have impaired vascular relaxation. The animals are salt-sensitive and 
develop kidney damage which is reversed by RAS blockade (Cheng et al. 2001). 
Wistar rats were used as a normoglycemic controls. 
4.1.2 Animal welfare 
Spontaneously diabetic Goto-Kakizaki rats were purchased from Taconic M&B 
Laboratory Animals and Services for Research, Ry, Denmark. Nondiabetic Wistar 
rats were purchased from Harlan, USA. All rats had free access to standard chow 
(Harlan, Germany) and drinking water. 
This investigation conforms to the guide for the care and use of laboratory 
animals published by the US National Institutes of Health (NIH publication No. 85-
23, revised 1996). The protocols were approved by the Animal Experimentation 
Committee of the University of Helsinki, Finland, and the Provincial State Office of 
Southern Finland. 
46 
 
4.1.3 Designs of the studies 
Study 
# 
Strain Group Treatment Follow-
up 
(weeks) 
I 
Goto-Kakizaki GK  4 
Wistar WIS  4 
II 
Goto-Kakizaki GK MI  12 
Goto-Kakizaki GK SHAM  12 
Wistar WIS MI  12 
Wistar WIS SHAM  12 
III 
Goto-Kakizaki GK MI  12 
Goto-Kakizaki GK MI + Levo Levosimendan 1 mg/kg 12 
Goto-Kakizaki GK SHAM  12 
Goto-Kakizaki GK SHAM + 
Levo 
Levosimendan 1 mg/kg 12 
Wistar WIS MI  12 
Wistar WIS MI + Levo Levosimendan 1 mg/kg 12 
Wistar WIS SHAM  12 
Wistar WIS SHAM + 
Levo 
Levosimendan 1 mg/kg 12 
IV 
Goto-Kakizaki GK MI  4 
Goto-Kakizaki GK MI + Levo Levosimendan 1 mg/kg 4 
Goto-Kakizaki GK SHAM  4 
Goto-Kakizaki GK SHAM + 
Levo 
Levosimendan 1 mg/kg 4 
In all studies the animals were 8-week old at the start of the protocol. 
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4.2 Experimental myocardial infarction 
Experimental myocardial infarction (MI) was performed by left anterior descending 
(LAD) coronary artery ligation in male eight-week old GK or Wistar rats as 
described previously (Palojoki et al 2001). The operation was made under 
ketamine (65 mg/kg i.p.) and medetomidine (0.5 mg/kg i.p.) anaesthesia. Long-
acting insulin (1 IU/animal) was given two hours before anaesthesia to GK rats. 
Buprenorphine (0.02 mg/kg s.c.) was given twice a day for two consecutive days 
for post-operative analgesia. The rats that were alive 24 hours after the operation 
were randomized into study groups. 
4.3 Levosimendan dose 
Levosimendan (Orion Ltd, Espoo, Finland) was mixed in drinking water (10 mg/l) 
and given for oral consumption; this produced the daily dose of approximately 1 
mg/kg (each animal drank an average of 30 ml/day). The dose was chosen based 
on our previous experiments where levosimendan produced clinically relevant 
plasma concentrations and exerted clear therapeutic effects (Louhelainen et al. 
2007; Levijoki et al. 2001). Fresh levosimendan solution was prepared daily. 
4.4 Echocardiography 
Transthoracic echocardiography (Toshiba Ultrasound, Japan) was performed in a 
blinded fashion by the same technician, with all rats under isoflurane anesthesia 
(AGA, Riihimäki, Finland). Each animal underwent three separate measurements 
by detaching the transducer between each measurement, and three pictures were 
taken. Parameters needed for the calculation of left ventricular (LV) function and 
LV dimensions were measured from three systole-diastole cycles. A short-axis 
view of the left ventricle at the level of the papillary muscle was obtained (Gibson 
method). Two-dimensionally guided M-mode recording through the anterior and 
posterior walls of the left ventricle allowed us to measure the left ventricle (LV) 
end-systolic (LVESD) and end-diastolic (LVEDD) dimensions as well as 
interventricular septum (IVS), anterior wall (AW) and posterior wall (PW) 
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thickness. LV fractional shortening (FS), ejection fraction (EF), measures of LV 
systolic function, stroke volume (SV), end-diastolic volume (EDV), end-systolic 
volume (ESV) and cardiac output (CO), were calculated from the M-mode LV 
dimensions using the following equations: FS (%): [(LVEDD-LVESD) / LVEDD)] x 
100, EF (%): (SV/EDV), SV: EDV – ESV, EDV: 0.52 x (0.98 x (LVIDD/10) + 5.90) 
x (LVIDD/10)2,  ESV:  0.52 x  (1.14 x  (LVIDS/10)  +  4.18)  x  (LVIDS/10)2,CO: Heart 
rate x SV. (LVIDD: Diameter of short axis left ventricle in end-diastole), (LVIDS: 
Diameter of short axis left ventricle in end-systole). 
4.5 Blood pressure recordings 
Blood pressure was measured using a tail-cuff blood pressure analyzer (Apollo-
2AB Blood pressure analyzer, M179-2AB, IITC, Life Sciences, Woodland Hills, 
CA, USA). Blood pressure recordings were performed by the same technician at 
the same time of day. 
4.6 Sample preparations 
Urine samples were collected during a 24-hour period when the rats were seated 
in metabolic cages. Rats were anaesthetized with CO2/O2 (AGA, Riihimäki, 
Finland) and decapitated. Blood samples were collected in tubes containing 
ethylenediaminetetra-acetic acid (EDTA). Hearts were excised, washed with ice-
cold saline solution and blotted dry. After weighing, the hearts were snap-frozen in 
liquid nitrogen (molecular biology) or isopentane (immunohistochemistry). All 
samples were stored in -80C until assayed. 
4.7 Biochemical analyses 
Blood glucose was determined using a handheld test meter (Glucocard II®, 
Arkray, Japan and Contour, Bayer, Basel, Swizerland), plasma BNP (BNP-45, 
Peninsula Laboratories, Belmont, CA, USA), plasma renin activity (Angiotensin I 
RIA kit, Diasorin, Italy), serum aldosterone (Coat-a-Count Aldosterone RIA kit, 
DPC Biermann, Bad Nauheim, Germany) and serum insulin (Rat insulin RIA kit, 
Linco, St. Charles, Missouri, USA) were determined by radioimmunoassay 
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according to the instructions of the manufacturers. Urinary noradrenaline was 
analyzed using the isocratic ion-pair reversed-phase high-performance liquid 
chromatography method with electrochemical detection. Plasma samples were 
determined for levosimendan and its active metabolite OR-1896 by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) (Kivikko et al. 2003). 
4.8 Histology 
The hearts were fixed in 10% buffered formalin solution for histological analyses. 
Transversal 5-µm sections were cut from the paraffin-embedded left ventricle and 
stained with hematoxylin-eosin or picrosirius red. Infarct sizes were determined 
planimetrically from the picrosirius-red stained histological sections as described 
elsewhere (Palojoki et al 2001). Collagen volume fraction was determined by 
computerized software analysis (ImageJ, NIH) from picrosirius red –stained 
histological sections (x20 magnification). Cardiomyocyte cross sectional area was 
measured from transverse-cut tissue slides (6 slides from each group) by 
conventional light microscopy at 40x magnification.  
4.9 Immunohistochemistry 
Immunohistochemistry was performed on deparaffinised and rehydrated formalin-
fixed 5 µm thick myocardial sections as described in detail elsewhere 
(Finckenberg et al. 2003). For evaluating Sirt1 protein expression and localization 
primary polyclonal antibody against Sirt1 (Sir2alpha, Rabbit polyclonal, Upstate; 
1:200 dilution) and secondary biotinylated anti-rabbit antibody (Vector 
Laboratories Inc., California, USA) were used. The average percentages of Sirt1-
positive cardiomyocytes/total number of cardiomyocytes were calculated from 6 
separate fields of transverse left ventricular tissue sections using light microscopy 
(×40 magnification). Immunoperoxidase staining for p16INK4a was performed on 
frozen myocardial sections using a primary monoclonal p16INK4a antibody (Santa 
Cruz BT, Santa Cruz, CA, USA) and peroxidise –conjugated rabbit anti-mouse 
secondary antibody (DAKO A/S, Glostrup, Denmark). 
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4.10 Apoptosis microarray 
RNA from LV:s of 4-5 rats per group was extracted with Trizol (Gibco, Invitrogen, 
Carlsbad, CA, USA) and purified with RNeasy mini-kit (Qiagen N.V., Venlo, The 
Netherlands). RNA was reverse transcribed to cDNA and back to cRNA for 
microarray analysis using the Oligo GEArray for Rat Apoptosis –kit (Superarray, 
Frederick, MD, USA) containing 114 known, apoptosis-related genes. Samples 
were hybridized to separate GEArray plates overnight in a hybridization oven 
(Stratagene Personal Hyb, La Jolla, CA, USA) and scanned (Packard Biosciences 
ScanArray 4000, Boston, MA, USA). Data extraction and analysis were performed 
with the GEArray Expression Analysis Suite software (Superarray, Bethesda, MD, 
USA). Significant differences were tested with the Student’s t-test.  
4.11 Genome-wide microarray  
Total RNA was labelled and hybridized to rat whole-genome arrays (Rat 
Expression Array 230 2.0, Affymetrix, Santa Clara, CA, USA). Sample labelling, 
hybridization to chips and image scanning (GeneChip Scanner 3000, Affymetrix) 
were performed according to the manufacturer’s instructions. Expression values 
were calculated with the Robust Multichip Average (RMA) method and normalized 
per chip to the median and analyzed with Genespring 7.2 (Agilent, Santa Clara, 
CA, USA). Microarray hybridisations were performed using 4 MI samples, 4 sham 
samples, 3 sham + levosimendan samples and 3 MI + levosimendan samples. 
Differentially expressed probe sets were selected based on filtering by the 
parametric statistical analysis not assuming equal variances (Welch-type t test) 
with P<0.05 as a threshold for significance, followed by filtering for fold change 
(±1.2 fold) between the compared groups. The list of up- and downregulated 
probe sets were inspected for the enriched canonical pathways of the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) among the genes using the ´David 
6.7´program (NIAD, (NIH), MD, USA). Our analysis identified the canonical 
pathways that were most significant to the data set. The analysis was performed 
for up- and down-regulated gene sets separately. 
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4.12 TUNEL staining 
Cardiomyocyte apoptosis was assessed by the terminal deoxynucleotide 
transferase mediated ddUTP nick end labeling (TUNEL) assay as previously 
described elsewhere (Kytö et al. 2004). In brief, apoptotic nuclear DNA strand 
breaks were end-labeled with digoxigenin-conjugated dideoxy-UTP by terminal 
transferase and visualized immunohistochemically with digoxigenin antibody 
conjugated to alkaline phosphatase. The assay was standardized with the use of 
adjacent tissue sections treated with DNase I to induce DNA fragmentation as a 
positive control for apoptosis. The proportion of TUNEL-positive cardiomyocytes 
was calculated from transverse left ventricular tissue sections using light 
microscopy (×20 magnification) with an ocular grid. Cardiomyocyte origin of the 
apoptotic cells was identified by the presence of myofilaments surrounding the 
nucleus. The proportion of apoptotic cardiomyocytes was counted in the border 
zones of infarct scars and in the remote non-infarct myocardium (Palojoki et al. 
2001). 
4.13 Western blotting 
Myocardial sample lysate from left ventricles of GK and Wistar rats were 
electrophoretically separated by SDS-PAGE. Proteins were transferred to a PVDF 
membrane (Immobilon-P®, Millipore, Bedford, MA, USA) and blocked in 5% non-
fat milk-TBS - 0.01% Tween-20® buffer. The membranes were probed with the 
following antibodies:  
anti-caspase-3 (Upstate-Millipore), anti-Bax (Abcam), anti-phospho-
FKHRL/FOXO3a (Cell Signaling Technologies (CST)), anti-FKHRL/FOXO3a 
(CST), anti-Akt (CST), anti-phospho-Akt (CST), anti-p38 (CST), anti phospho-p38 
(CST). Tubulin was used as loading control (Anti-alpha tubulin, Abcam, 
Cambridge, UK). Horseradish peroxidase-conjugated anti-rabbit secondary 
antibody (Chemicon) was subjected to enhanced chemiluminescence solution 
(ECL plus, Amersham Biosciences, Buckinghamshire, UK) and exposed to x-ray 
film (Hyperfilm-ECL, Amersham). We quantified the relative protein expression in 
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separate samples from the x-ray film by densitometry (Synoptics, Cambridge, 
UK). 
4.14 Electrophoretic mobility shift assay (EMSA) 
Electrophoretic mobility shift assay (EMSA) was used to determine the DNA-
binding properties of nuclear FOXO3a transcription factor. Nuclear proteins were 
extracted by grinding left ventricle samples from the remote area in liquid nitrogen 
and incubating in a buffer with protease inhibitor (Complete®, Roche), membrane 
proteins were solubilized with Nonidet P-40 (Roche Diagnostics GmBH, 
Mannheim, Germany). 5 ?g of nuclear extracts were incubated in binding buffer (3 
mM Tris pH 7.5, 50 mM NaCl, 5% Glycerol, 1 mmol/l EDTA, 0.01 mg/ml Poly[d(I-
C)], 1 mmol/l DTT, 2 mg/ml BSA) and 1.25 fmol of digoxigenin-tagged FOXO3a 
oligonucleotides: 5´-DIG-ATT GCT AGC AAG CAA AAC AAA CCG CTA GCT TA-
3´and 5´-DIG-TAA GCT AGC GGT TTG TTT TGC TTG CTA GCA AT-3´ 
(Oligomer, Helsinki, Finland). After 30’ incubation, the samples were 
electrophoretically separated by 5% SDS-PAGE and blotted to a nylon membrane 
(Hoefer semiPhor, TE77, Amersham Biosciences). Nuclear proteins were cross 
linked to the membrane for 10’ in 254 nm UV-light. The membrane was probed 
with rabbit Anti-digoxigenin-AP-conjugate (Roche) for 30 min. and incubated in 
detection reagent (CDP Star, Roche) and exposed to an x-ray film (Kodak Inc., 
Japan). The indication reaction was done by incubating the samples with tagged 
and untagged oligonucleotides and probing with rabbit anti-FKHRL1 (sc-11351, 
Santa Cruz, CA, USA). 
4.15 Quantitative RT-PCR 
Total RNA from the rat hearts were extracted with Trizol® (Gibco, Invitrogen, 
Carlsbad, CA, USA), treated with DNAse 1 (Deoxyribonuclease 1, Sigma 
Chemicals Co., St Louis, MO, USA) and reverse transcribed to cDNA by reverse 
transcription enzyme (Enhanced avian HS RT-PCR kit, Sigma Chemicals Co, 
Saint Louis, MO, USA). One ?l of cDNA was subjected to quantitative real time 
polymerase chain reaction using the Lightcycler® instrument (Roche diagnostics, 
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Neuilly sur Seine, France) for detection of atrial natriuretic peptide (ANP), 
connective tissue growth factor (CTGF), interleukin-6 (IL-6), ProRenin receptor, 
AT1 receptor, ACE, ACE2, NEP, HO-2, and ribosomal 18S mRNA. The samples 
were amplified using FastStart DNA Master SYBR Green 1 (Roche diagnostics) 
according to the protocol of the manufacturer. 
4.16 Statistical analyses 
Statistics were performed by software program analysis (GraphPad Prism, San 
Diego, CA, USA). Student’s t-test was used to assess difference in mean values 
between two groups. One-way analysis of variance (ANOVA) and Neuman-Keuls 
post test were used to assess the difference in means when three or more groups 
were compared. A significant difference between groups was considered when 
the P value was <0.05. 
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5 Results and discussion 
For a summary table of results from studies 1-4, refer to the end of section 5. 
5.1 Survival 
Ligation of the left anterior descending artery and subsequent myocardial 
infarction of the anterior wall resulted in a relatively high 24 –hour mortality. 24 –
hour survival in GK rats was 35% vs. 56 % in Wistar rats (P<0.05) (study 3). The 
difference between the groups was significant, and the results indicate that 
diabetic GK rats have an increased risk of fatal MI. In each study, 1-2 animals 
died during follow-up. After the follow-up of 4 or 12 weeks the size of the infarct 
areas were evaluated by planimetry. Levosimendan was introduced 24 hours after 
experimental MI/sham operation. No differences in infarct sizes between the 
groups were found, and levosimendan did not influence survival or infarct size.  
Discussion 
A fairly large meta-analysis recently showed that diabetes is a risk factor for 
mortality following acute coronary syndromes (UAP, NSTEMI, STEMI) (Donahoe 
et al. 2007). My results are in line with this notion. A prior study showed that 
levosimendan decreased mortality 312 days post-MI (Levijoki et al. 2001). My 
studies did not examine long-term mortality; the longest follow-up was 84 days 
which may explain the absent effect on survival. 
5.2 Plasma concentration of levosimendan 
In levosimendan –treated rats the terminal plasma concentration of the stable 
metabolite OR-1896 was 20.4 ± 4.0 ng/ml (study 3). The same dosing (10 mg/ml 
p.o. corresponding estimated 1 mg/kg) was used in study 4. 
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5.3 Blood pressure and cardiac function 
In study 1, systolic blood pressure was 8-10 mmHg higher in 10-12 week old GK 
rats compared to Wistar controls. This finding was confirmed in studies 2 and 3 
where systolic blood pressure in 20-week old sham-operated GK rats was 
increased by 5 mmHg and 8 mmHg respectively. In studies 1-3 systolic blood 
pressure in GK rats ranged from 138-150 mmHg and in Wistar from 127-144 
mmHg. These results confirm the notion that GK rats develop spontaneous 
hypertension. In studies 2 and 3, MI resulted in a reduction of ca. 18 mmHg in 
systolic blood pressure in GK rats whereas in study 4, MI induced a 3 mmHg 
reduction in systolic blood pressure. These differences are explained at least in 
part by the difference in follow-up time, 12 weeks in studies 2 and 3 vs. 4 weeks 
in study 4. Levosimendan treatment did not alter systolic blood pressure in post-
MI GK rats in study 3 and 4. Levosimendan treatment did slightly but significantly 
lower systolic blood pressure in sham-GK rats in study 3 but not in study 4. 
Levosimendan treatment increased heart rate in GK + MI rats in study 3 (12 
weeks follow up) but not in study 4 (4 weeks follow-up), and did not influence 
heart rate in Wistar + MI or sham-operated rats.  
Transthoracic echocardiography revealed an increase in diastolic volume in the 
LV of GK rats compared to Wistar indicating a dilated left ventricle (study 1). 
Furthermore plasma BNP was increased in GK rats compared to Wistar indicating 
volume overload. Systolic function was decreased in GK rats compared to Wistar 
in study 1 (EF% 59 vs. 83). Experimental MI by LAD ligation induced thinning of 
the anterior wall of the left ventricle in studies 2-4. In GK rats, ejection fraction 
(EF) decreased to ca. 23% at week 1 and 25% at week 4 post MI (study 3-4) and 
increased slightly at 12 weeks post-MI to reach 42% (study 2-3) (Figure 7). LAD 
ligation in Wistar rats produced similar results. 
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Figure 7. Effects of levosimendan on ejection fraction (EF), a measure of systolic function, 
1, 4 and 12 weeks after experimental myocardial infarction (MI) in diabetic Goto-Kakizaki 
(GK) rats. Values are presented as means ±SEM, * denotes P<0.05  vs.  GK  SHAM,  #  
denotes P<0.05 vs. GK MI.  
 
Discussion 
Diastolic dysfunction, the hallmark in type 2 diabetes, is a consequence of 
reduced compliance of the ventricular wall most often caused by LVH and/or 
fibrosis that results in increased LV end-diastolic pressure (LVEDP) and primariliy 
a reduction in early to late atrial filling (E/A ratio) (For a review see Fang et al. 
2004). Earlier studies with GK rats have shown an increased susceptibility to 
diastolic dysfunction after dietary high sodium intervention and concomitant 
increase in blood pressure (Grönholm et al. 2005). Systolic dysfunction withholds 
a degree of diastolic dysfunction and others have shown that systolic dysfunction 
occurs in STZ-induced diabetes (Joffe et al. 1999; Wold et al 2001; Hoit et al. 
1999). In these studies I did not examine LVEDP and E/A by echocardiography; 
however the results indirectly indicated the presence of diastolic dysfunction in 
diabetic GK rats, which I observed by increased fibrosis, LVH and systolic 
dysfunction (study 1). However, systolic dysfunction was not present in sham-GK 
rats in studies 2-3, providing a notion of the genetic variation in the rat model of 
the inbred GK rats. This notion is supported by the findings in a study which 
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proposed that cardiac dysfunction is accelerated in Goto-Kakizaki rats post-MI 
(Chandler et al. 2007); my studies did not show significant differences in 
echocardiography parameters after MI in GK vs. Wistar rats. 
Levosimendan ameliorated systolic dysfunction in post-MI GK rats, with ejection 
fraction reaching 41% at 4 weeks post-MI (study 4) and 71% 12 weeks post-MI 
(study 3) (Figure 7). Additionally levosimendan increased cardiac output in post-
MI GK rats (study 3-4). In study 3, the increase in cardiac output can be partly 
explained by the increase in heart rate, however in study 4 levosimendan did not 
alter heart rate. In Wistar rats Levosimendan increased systolic function less 
efficiently; ejection fraction was increased from 35% (sham) to 47% (MI) (study 3), 
cardiac output however was increased from 277 ml/min to 376 ml/min in Wistar + 
MI without increased heart rate. In sham-operated GK rats levosimendan did not 
alter echocardiography parameters, whereas in sham -operated Wistar rats EF 
was increased after levosimendan treatment. 
Discussion 
The results showed that 4 weeks and 12 weeks of levosimendan treatment 
efficiently ameliorated cardiac dysfunction in GK rats with post-MI heart failure. 
Systolic blood pressure was not changed in post-MI rats, however heart rate was 
increased in the 12 –week follow up but not in the 4 –week study in GK + MI rats. 
The reason for this was unclear and the increase in heart rate was absent also in 
Wistar rats 12 –weeks post MI. Levosimendan is a known vasodilator through 
opening KATP –channels and inhibiting PDEIII; these factors could explain the 
increase in heart rate via compensatory sympathetic activation. However, a recent 
study has shown that in the clinical setting levosimendan does not increase 
sympathetic activity (Despas et al. 2010). Taken together the inotropic actions of 
levosimendan were evident and presumably derived from the known effects of 
sensitization of cardiac troponin C to calcium, without excluding the role of an 
increase in heart rate. 
58 
 
5.4 Blood glucose and insulin 
The non-obese Goto-Kakizaki rat has been shown to exhibit the polygenic 
features of type 2 diabetes including insulin resistance, abnormal glucose 
metabolism and spontaneous hyperglycaemia (Goto Y et al. 1976; Galli et al. 
1999). In my studies the GK rats developed mild hyperglycemia with fasting 
plasma glucose values ranging from 7.3 mmol/L to 10.5 mmol/L in 12-20 -week 
old animals. In control non-diabetic Wistar rats fP-Glucose ranged from 3.3 to 4.9 
mmol/L (studies 1-4). Serum insulin levels were slightly increased in GK rats, with 
values ranging from 2.0 to 4.1 ng/ml compared to 1.6 to 3.4 ng/mL in 12-20 -week 
old non-diabetic Wistar controls (studies 1-2). In  post-MI GK rats, serum insulin 
was increased compared to Wistar MI (study 2). Experimental myocardial 
infarction did not alter terminal plasma glucose values. Levosimendan did not 
influence plasma glucose or serum insulin concentration (study 3 and 4). These 
results justify the use of the GK rat as a model to study type 2 diabetes and the 
use of non-diabetic Wistar rats as their controls. 
5.5 Left ventricular hypertrophy 
Cardiac hypertrophy was evaluated by heart weight to body weight ratio and 
histologically by examining average cardiomyocyte cross sectional areas in the 
left ventricle. In the 12 –week old diabetic GK rats cardiac hypertrophy was 
evident due to increased heart weight to body weight ratio (+33% compared to 
Wistar) and increased cardiomyocyte cross sectional area (+22%) (study 1). In 
GK rats the increase in systolic blood pressure (+10 mmHg) may have played a 
role in the development of LV hypertrophy. In GK rats, experimental myocardial 
infarction further exacerbated LV hypertrophy 1.4 –fold as revealed by 
cardiomyocyte cross sectional area of the non-infarct area. In Wistar rats, MI 
increased LV hypertrophy 1.3 –fold. Average cardiomyocyte cross sectional area 
in Wistar + MI rats was the same as in GK sham rats. Levosimendan ameliorated 
LV hypertrophy in GK rats 4 and 12 weeks post-MI (studies 3-4) without changes 
in blood pressure (Figure 8). Notably levosimendan also ameliorated LV 
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hypertrophy in sham-operated GK rats; in study 3 this was associated with a 
decrease in systolic blood pressure whereas in study 4 no change in systolic 
blood pressure was found. Levosimendan did not decrease cardiomyocyte cross 
sectional area or heart weight to body weight ratio in Wistar rats. MI resulted in an 
increase in plasma BNP and ANP mRNA levels in GK rats. Levosimendan 
markedly reduced BNP in all GK + MI rats and ANP mRNA expression in GK + MI 
rats in study 3. 
 
 
Figure 8.  Effects of levosimendan on left ventricular hypertrophy 1, 4 and 12 weeks after 
myocardial infarction (MI) in diabetic Goto-Kakizaki (GK) rats as evaluated by 
cardiomyocyte cross sectional area. Values are presented as means ±SEM, * denotes 
P<0.05 vs. GK SHAM, # denotes P<0.05 vs. GK MI. 
 
Discussion 
The results in these studies showed that diabetic GK rats develop spontaneous 
LV hypertrophy which is one of the hallmarks of diabetic cardiomyopathy. MI in 
both rat strains exacerbated LV hypertrophy to a similar extent. These results 
were in line with a previous study where cardiac hypertrophy increased 
comparably in GK and WKY rats 8 and 20 weeks post MI (Chandler et al. 2007). 
The mechanisms that promote LV hypertrophy in diabetes have been proposed to 
include increased ROS production, increased insulin signalling and RAS 
activation (for a review see Boudina et al. 2010). My results showed a modest 
increase in serum insulin concentration in GK rats with MI (study 2) and a modest 
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increase in systolic blood pressure in GK vs. Wistar rats, both of which may have 
played a role in the increase in LVH. However, in GK rats with MI, LVH was 
increased further while systolic blood pressure remained unchanged compared to 
Wistar, providing an indication of a blood pressure –independent mechanism in 
GK rats. 
Levosimendan reduced LVH in all GK rats. In GK rats with MI, levosimendan did 
not reduce blood pressure whereas in GK sham –rats levosimendan slightly 
decreased systolic blood pressure in study 3. Therefore I may propose that the 
LVH reducing effects of levosimendan in GK rats was mediated both through 
blood pressure dependent and independent mechanisms. These results are 
consistent with previous results where levosimendan was shown to reduce LV 
hypertrophy in salt –sensitive Dahl/Rapp rats (Louhelainen et al. 2007). However 
the mechanism through which levosimendan was able to reduce LV hypertrophy 
in sham –operated diabetic GK rats is unclear. The reduction in ANP and BNP 
further provide indirect evidence that levosimendan acts as a negative regulator of 
LV hypertrophy. These results bring evidence that levosimendan 1) attenuates 
post-MI LV remodeling and 2) has beneficial effects on diabetic cardiomyopathy 
by decreasing LV hypertrophy. 
5.6 Calcium handling proteins 
The expression of myocardial SERCA2a and NCX proteins were studied in GK 
and Wistar rats ±MI and ±levosimendan. Myocardial SERCA2 and NCX protein 
expression were not changed in Wistar vs. GK rat heart at baseline, however 
SERCA2 protein expression was decreased by 30% and NCX protein expression 
was increased by 74% after MI in GK rats (SERCA2/NCX ratio 0.47 vs. 1.22, 
P<0.05).  
Discussion 
A decrease in SERCA2 and/or an increase in NCX protein have been associated 
with decreased contractitily in the failing heart (for a review, see Bers et al. 2009). 
My results are in line with previous studies showing a reduced SERCA2/NCX ratio 
in post-MI mice with impaired insulin signalling (Sena et al. 2009). Increased free 
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ROS and protein modification in the SR of cardiomyocytes has been proposed as 
a potential mechanism for this effect (Kaplan et al. 2003). Levosimendan 
prevented the changes in SERCA2 and NCX protein expression in GK + MI rats. 
5.7 Sympathetic and renin angiotensin system 
Sympathetic nervous system activation was studied by examining 24h urinary 
noradrenaline excretion (U-NA); a non-significantly lower U-NA content in GK rats 
at baseline (study 1) was aggravated at 12 weeks after MI, at which time U-NA 
was significantly decreased in GK + MI rats compared to Wistar + MI. MI 
increased U-NA in Wistar but not in GK rats. I did not study the effect of 
levosimendan on U-NA. These results provide an indication of sympathetic 
nervous system dysregulation in diabetic GK rats. 
The circulating RAAS activity was studied by examining plasma renin activity 
(PRA) and serum aldosterone in GK and Wistar rats. My results showed no 
changes in PRA or aldosterone in GK vs. Wistar rats at baseline. In GK + MI rats 
PRA was increased vs. Wistar + MI (study 2). RT-PCR showed an increase in 
angiotensin converting enzyme mRNA expression in GK rats 4 weeks after MI. S-
aldo was further increased after MI in GK and Wistar rats (study 2-4). 
Levosimendan did not affect PRA or S-aldo in sham or MI operated rats.  
Discussion 
Others have shown that the GK rat has a modest hyperaldosternism (Grönholm et 
al. 2005) and my results suggest that the increase in S-aldo is further increased 
after MI and is associated with a low PRA. The slightly higher aldosterone levels 
may explain the mild increase in systolic blood pressure in GK rats. Previous 
studies have suggested that tissue RAAS activation is involved in the 
pathogenesis of post-MI heart failure (for a review see Sun et al. 2010) and have 
shown that diabetes is associated with an increase in local renin-angiotensin 
system activation (Sechi et al. 1994; Khatter et al. 1996; Fiordaliso et al. 2000). I 
used a microarray based approach to study the whole genome of GK rat 
myocardial tissue (study 4). In GK + MI rats treated with levosimendan my results 
showed an increase in angiotensin II receptor 1 (Agtr1), thimet oligopeptidase 1 
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(Thop1) and chymase 1 (Cma1) mRNA expression. However, the increase in At1r 
was not confirmed by RT-PCR. My results showed an increase in mRNA 
expression of the Mas receptor and neutral endopeptidase (Nep) enzyme in 
levosimendan treated GK + Sham (study 4). The Mas receptor is a target of Ang 
(1-7) and exerts anti-hypertrophic and vascodilatory effects. Ang(1-7) is produced 
from AngI by enzymes including Thop1 and Nep and prolyl oligopeptidase 
(Ferrario et al. 1998). These results suggest that levosimendan may attenuate LV 
remodelling partly through the induction of the Ang(1-7) - Mas receptor –axis 
which mediated a decrease in LVH, this was shown in levosimendan treated GK 
sham rats (studies 3-4). I did not examine the tissue RAS in non-diabetic Wistar 
rats in this study. 
5.8 Apoptosis 
The protein expression of caspase-3, one of the main effectors of the apoptotic 
cascade, was increased in GK vs. Wistar rat hearts together with proapototic 
protein p53 and Bax. Furthermore, apoptosis –specific microarray revealed a 
marked positive shift in the mRNA expression of apoptotic genes in GK vs. Wistar 
rat hearts (study 3). However these findings did not translate into an increase in 
apoptosis since TUNEL staining failed to reveal an increase in apoptotic nuclei in 
GK rat myocardial samples (study 1). I did however find that the negative 
regulator of p53, namely Sirt1 deacetylase was overexpressed and that the 
acetylation level of p53 was decreased in GK rats; this offers a possible 
explanation why no overt apoptosis was evident in the GK rat heart. 
MI further increased the expression of Caspase-3 and Bax and produced a 
positive shift in the profile of apoptotic gene expression in both GK and Wistar rat 
heart samples. MI increased myocardial apoptosis in the infarct border zone (10 –
fold increase) and in the remote area (4 –fold increase) as demonstrated by 
TUNEL staining (Figure 9). There were a higher number of apoptotic nuclei in 
both the border zone and in the remote area in GK rats compared to Wistar rats. 
Levosimendan decreased the amount of TUNEL positive cells in the infarct area 
and in the remote area in both GK and Wistar rats after MI. Levosimendan 
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produced a negative shift in the expression of apoptotic genes which was 
determined by apoptosis –specific microarrays. These results provide evidence 
that diabetic cardiomyopathy in the GK rat is associated with an increase in 
apoptotic signalling, this was shown by increased gene expression of the 
apoptotic cascade and increased caspase-3 and Bax protein expression. The 
situation was exacerbated by MI when overt sustained cardiomyocyte apoptosis 
was evident 12 weeks post-MI in the infarct border zone and in the remote area in 
GK rats compared to non-diabetic Wistar rats.  
Discussion 
These results are in line with the notion that diabetic cardiomyopathy is 
associated with an increase in apoptosis. The mechanism behind the increase in 
apoptotic signalling was not studied here. However, earlier studies have shown 
that diabetes –induced lipo -and glucotoxicity, mitochondrial dysfunction and RAS 
activation increases the amount of reactive oxygen species (ROS) which in turn 
activates the apoptotic signalling process (for reviews, see Santos et al. 2003; 
Rolo et al. 2006 and Dobrin et al. 2010). 
 
Figure 9. Effects of levosimendan on myocardial apoptosis in the remote area and infarct 
border zone 12 weeks after myocardial infarction (MI) in diabetic Goto-Kakizaki (GK) rats 
as evaluated by TUNEL-staining.  Values are presented as means ±SEM, * denotes 
P<0.05 vs. GK SHAM, # denotes P<0.05 vs. GK MI. 
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12 weeks of levosimendan –treatment was sufficient to decrease the amount of 
apoptotic cells in the border zone and in the remote area in post-MI GK and 
Wistar rats. Maytin and Collucci have shown that levosimendan opposes 
cardiomyocyte apoptosis, a feature that was absent when glibenclamide was 
used to inhibit KATP-channels (Maytin et al. 2005). These findings are consistent 
with in vitro studies which show that opening of mitochondrial KATP channels 
protects from ischemia reperfusion injury through following reduction in reactive 
oxygen species and subsequent inhibition of apoptosis (Akao et al. 2001). I may 
speculate that the beneficial role of levosimendan in GK rats may be, at least in 
part explained by the baseline mitochondrial dysfunction that is ameliorated by 
beneficial effects mitochondrial on KATP –channels. 
5.9 Fibrosis 
The results showed that the mRNA expression of connective tissue growth factor 
(CTGF) was increased in GK rat hearts and that fibrosis was accelerated after MI 
in GK rat LV tissue compared to Wistar. Increased CTGF mRNA expression in 
GK rats compared to Wistar rats (study 1) was further increased by MI (studies 2-
3). IL-6 mRNA expression was slightly increased in GK + MI rats (study 2). 
Collagen volume fraction measurement from the remote area in myocardial tissue 
slides revealed a higher degree of interstitial and perivascular fibrosis in GK vs. 
Wistar rats at 12 weeks post MI (study 2). In levosimendan –treated rats, the 
increase in collagen volume fraction was absent after MI (study 4) and 
levosimendan tended to decrease collagen volume fraction in sham GK rats 
(Study 3). Levosimendan reduced CTGF mRNA expression in GK + MI rats but 
not in Wistar + MI rats (studies 3). In addition, IL-6 mRNA expression was 
decreased in levosimendan –treated GK + MI rats compared to GK + MI rats 
(study 3). 
Discussion 
Studies in humans have shown increased collagen deposition correlating with 
diastolic dysfunction in type 2 diabetic patients (Regan et al. 1977; Gonzalez-
Vilchez et al. 2005). Animal studies of type 2 diabetes have indicated that 
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increased cardiac fibrosis may occur spontaneously already at the pre-diabetic 
stage (Mizushige et al. 2000). My results are in line with these studies. 
Furthermore, the beneficial effects of levosimendan on reduction of cardiac 
fibrosis were evident. Levosimendan was able to reduce the increase in post MI - 
CTGF and IL-6 mRNA expression and reduce interstitial fibrosis as measured by 
collagen volume fraction. Studies have shown that an increase in free ROS after 
MI increases apoptotic and necrotic cell death and following fibrosis by activating 
several cytokines including TNF-alpha and IL-6 (for a review, see Hori et al. 
2009). The beneficial effects of levosimendan on apoptosis and fibrosis may be, 
at least in part, attributed to the opening of mitochondrial KATP –channels and the 
subsequent beneficial effect on energy homestasis and reduction of build-up of 
reactive oxygen species. Although other mechanisms cannot be excluded. 
5.10 Senescence 
I studied the senescence in the myocardial tissue samples from GK and Wistar 
rats with MI treated  with levosimendan. In GK + MI rats the mRNA expression of 
P16INK4a was increased 3 –fold compared with GK sham rats. Levosimendan 
reduced the MI –induced increase in P16INK4a mRNA  expression  in  GK  rats.  In  
Wistar rats, MI did not influence P16INK4a mRNA expression.  
Discussion 
The marker of senescence studied here, namely P16INK4a, is a known tumour 
suppressor and increases apoptosis in response to aging (Sharpless 2004). I 
showed here that a sustained increase in cardiomyocyte apoptosis was 
associated with an increase in P16INK4A in post –MI GK rats. These findings are 
interesting and provide an indication that the ability of levosimendan to decrease 
cardiomyocyte apoptosis may be mediated at least in part by suppression of the 
P16INK4a pathway in the diabetic myocardium.   
5.11 Akt and FOXO3a 
I studied the activity and post-translational modification of FOXO3a, a 
transcriptional regulator downstream of the insulin receptor - PI3K/Akt kinase 
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pathway in GK and Wistar rat hearts. Data from study 2 showed that in the GK rat 
heart phosphorylation of FOXO3a was reduced compared to Wistar hearts. 
Further, my results showed that the nuclear localization and DNA binding of 
FOXO3a was increased in GK rat myocardium (study 1). In study 2 I examined 
the phosphorylation and localization of FOXO3a and the phohsphorylation of Akt 
kinase and protein expression of the Akt kinase deactivator protein PTEN in GK 
and Wistar rats 12 weeks after MI. The results showed that Akt –kinase was 
dephosphorylated in GK + MI rats compared to Wistar + MI and that this was 
associated with increased FOXO3a nuclear translocation and DNA binding in GK 
+ MI rats compared to sham-operated GK rats and Wistar + MI rats. Furthermore I 
showed that the phosphatase PTEN protein expression was increased in the GK 
+ MI rat heart (study 2). These results provided evidence that Akt 
dephosphorylation was associated with FOXO3a dephosphorylation and nuclear 
translocation in GK rat myocardium after MI. The increase in nuclear, DNA bound 
FOXO3a could explain, at least in part, the increase in cardiomyocyte apoptosis 
found in the post-MI GK rat. These results were confirmed in study 3, where 
microarray analysis of apoptotic gene expression showed an increase in the 
expression of FOXO3a –associated apoptotic genes such as Bcl2l11, Fadd and 
Bad in GK + MI vs. GK sham rat hearts (study 3). In levosimendan –treated GK + 
MI rats, the nuclear localization of FOXO3a was decreased compared to 
untreated GK + MI rats (study 3). Furthermore, levosimendan suppressed the 
mRNA expression of FOXO3a related apoptotic genes Bcl2l11 and Tnfrsf12a 
when compared with GK + MI rats. 
Discussion 
Earlier studies have shown that the diabetic GK rat heart is insulin resistant with 
decreased insulin receptor and IRS-1 protein content and decreased PI3K 
phosphorylation upon insulin stimulation (Desrois et al. 2004). However the same 
study showed that Akt phosphorylation is not decreased in GK rat hearts. These 
results were consistent with my results that showed no change in Akt 
phosphorylation between sham –operated Wistar vs. GK rats (study 2). However, 
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I showed here that after MI the situation changes, as Akt phosphorylation was 
decreased in the GK rat heart 12 weeks post operation. This could prove 
important since Akt plays a key role as an antiapoptotic stress response protein 
when activated through phosphorylation. The decrease in Akt phosphorylation 
could be explained, at least in part, by the finding that GK + MI rat hearts showed 
an increase in PTEN protein expression, a phosphatase protein that 
dephosphorylates PIP3 and consequently Akt. The mechanism for the increase in 
PTEN protein expression was not studied further and remains unclear. 
Increase in cardiomyocyte apoptosis, Akt-FOXO3a dephosphorylation and 
FOXO3a translocation in GK rat hearts were consistent with the notion that 
phosphorylated FOXO3a is translocated to the cytoplasm whereas 
dephosphorylated FOXO3a is localized to the nucleus where it may take part in 
regulation of apoptotic gene expression (van der Heide et al. 2004). My results 
showed that overt apoptosis was increased in the remote area of the myocardium 
in post-MI GK rats and that the GK rat without MI showed increased apoptotic 
gene expression and increased Caspase-3 and Bax protein expression (study 2). 
The increase in nuclear FOXO3a translocation and DNA binding was associated 
with an increase in FOXO3a-regulated proapoptotic gene expression in GK + MI 
rat hearts compared to Sham (study 3). Earlier studies have shown that stress 
stimuli such as oxidative stress, heat shock or growth factors increase nuclear 
localization of FOXO3a (Brunet et al 2004). Nuclear localization of FOXO3a is 
associated with induction of the superoxide dismutase 2 (SOD2) gene, the 
product of which reduces toxic superoxide to hydrogen peroxide. The ability of 
FOXO3a to detoxify ROS is important in an environment with high oxidative stress 
such as diabetes, and this may provide a mechanism which enables the 
increased nuclear FOXO3a shuttling seen here. One potentially adverse effect of 
nuclear FOXO3a is the increased expression of apoptotic genes. FOXO3a-
regulated increase in apoptotic gene expression is enhanced by acetylation of 
nuclear FOXO3a by CBP and p300 in oxidative stress states (Brunet et al. 2004; 
Huang et al. 2007). Sirt1, a histone deacetylase and longevity factor has been 
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shown to inhibit FOXO3a –mediated apopotic gene expression by deacetylating 
FOXO3a (Brunet et al. 2004; Motta et al. 2004). It has been proposed that 
modulation of FOXO3a transcriptional regulation by Sirt1 is one of the 
mechanisms for Sirt1 –mediated increase in cell survival. My results showed here 
that Sirt1 protein expression is increased in diabetic GK rat hearts. Furthermore I 
showed that one of the targets of Sirt1, namely the proapoptotic p53 tumor 
suppressor was deacetylated in GK rat hearts (study 1) and GK + MI rat hearts 
(study 2). 
Data from study 3 showed that levosimendan was able to suppress the nuclear 
localization of FOXO3a. Previously I have shown that in levosimendan –treated 
rats cardiomyocyte apoptosis was decreased markedly. These results were 
confirmed by the notion that mRNA expressions of Bcl2-like 11 (Bcl2l11) and the 
tumor necrosis factor receptor subfamily 12a (Tnfrsf12a) were reduced. In 
conclusion, levosimendan, by mechanisms that are not entirely clear, was able to 
partly inhibit the nuclear localization of FOXO3a and suppress the increase in 
FOXO3a –induced apoptotic gene expression. 
5.12 Sirtuin 1 and P53 
My results showed that Sirtuin 1 (Sirt1) protein expression was increased in 
diabetic GK rat myocardial tissue compared to Wistar (study 1). This finding was 
consistent with the results in study 2 which showed an increase in Sirt1 protein in 
myocardial tissue from sham-operated GK rats vs. Wistar sham. The study further 
showed that p53 protein expression was increased in GK rat myocardium 1.9 fold. 
The increases in Sirt1 and p53 protein expressions were associated with a 
decrease in p53 –acetylation at the Sirt1 –preferred lysine sites K373/K382 in GK 
(study 1). As indicated earlier, GK rats showed no overt cardiomyocyte apoptosis, 
and therefore Sirt1 –mediated inhibition of p53 and thus attenuation of apoptosis, 
may have played a role in the myocardium in these rats. However since Sirt1 
induces growth its anti-apoptotic effect may have come with the cost of increased 
cardiomyocyte hypertrophy, although other factors such as hypertension are likely 
involved. 
69 
 
Furthermore, Sirt1 protein was overexpressed in GK + MI rats compared to Wistar 
MI (study 2) and localized to the nucleus which I demonstrated using western 
blots and immunohistochemical analysis. Study 2 showed that Sirt1 protein 
expression is upregulated both in the remote area and in the infarct area in GK + 
MI rats. The acetylation of the p53 protein was decreased in GK + MI rats 
consistent with the increase in Sirt1 protein. In GK + MI rats however, Sirt1 –
mediated p53 deacetylation was unable to suppress the increase in 
cardiomyocyte apoptosis as which I tested by TUNEL staining.  
Discussion 
Sirt1 protein expression has been shown to be increased in response to oxidative 
stress and in LV hypertrophy in dogs and rats (Alcendor et al. 2004; Alcendor et 
al. 2007). Increased oxidative stress in myocardium of GK rats has been shown in 
various studies, and the main contributing factors are hyperglycemia, increased 
FA, decreased antioxidant capability and defects in cardiomyocyte mitochondria 
(Bitar et al. 2004; Santos et al. 2003). Sirt1 acetylase activity is increased by a 
high NAD+/NADH ratio present in the oxidative stress environment. My results are 
consistent with this notion as I showed that Sirt1 protein overexpression was 
associated with increased Sirt1 deacetylase activity observed by the decrease in 
acetylated p53. Furthermore, hyperglycemia –induced increase in ROS is known 
to initiate p53 –mediated cardiomyocyte apoptosis (Frustaci et al. 2000; Fiordaliso 
et al. 2001). Accordingly my results provided evidence that in the GK rat 
myocardium p53 protein overexpression was associated with Sirt1 –mediated p53 
deacetylation and no overt cardiomyocyte apoptosis. However, 12 weeks after MI, 
Sirt1 – p53 deacetylation still occurred although cardiomyocyte apoptosis was 
increased. This indicates that other factors than p53 were responsible for the 
sustained increase in apoptosis in GK + MI rats in this setting. 
5.13 p38 Mitogen activated protein kinase 
Other researchers have suggested that p38 MAPK phosphorylation in response to 
oxidative stress in insulin resistant skeletal muscle is increased in diabetes 
(Henriksen et al. 2010). The results here showed that total p38 protein was 
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increased in GK and Wistar rats after MI compared to Wistar. Furthermore, data 
revealed for the first time that p38 MAPK phosphorylation is markedly increased 
in GK rat myocardium 12 weeks after MI but not in Wistar + MI rats (Study 2).  
Discussion 
Studies have previously shown that activation of the p38 MAPK increases 
apoptosis, fibrosis and the expression of CTGF and IL-6 mRNA (Tenhunen et al. 
2006). In addition p38 MAPK phosphorylation has been associated with 
decreased contractility (Liao et al 2002). Consistent with these studies my results 
showed an increase in apoptosis and fibrosis and non-significant modest 
increases in CTGF and IL-6  mRNA expression in GK + MI rats compared to 
Wistar + MI. Furthermore, my results are in line with other studies which have 
shown the involvement of p38 MAPK in hypertrophy (Kompa et al. 2008). Taken 
together these results provide evidence that the diabetic GK rat heart is 
susceptible to sustained p38 MAPK phosphorylation in response to myocardial 
infarction; a potentially adverse effect that could have been a cause for the 
increased apoptosis, hypertrophy and fibrosis seen here.  
5.14 Levosimendan and myocardial gene expression profile 
In levosimendan –treated GK + MI rats the most significantly enriched pathway 
was the renin-angiotensin system pathway (P=0.025) represented by three 
upregulated genes, namely the Agt1r, Cma1 and thop1 genes. The second most 
significantly enriched pathway was the glycerolipid pathway (P=0.036) with three 
downregulated genes, namely diacylglycerol kinase gamma (Dgkg), carboxyl 
ester lipase (Cel) and diacylglycerol kinase iota (Dgki). In levosimendan treated 
GK sham rats, the most enriched pathways included the  purine metabolism 
pathway (P=0.02) with 1.21-1.37 -fold upregulations of adenosine kinase (Adk), 
guanine monophosphate synthetase (Gmps), phosphodiesterase subtypes 3A 
and 4A and 4B (PDE3A/4A/4B), phosphoribosyl pyrophosphate amidotransferase 
(Ppat), polymerase II polypeptide H (Pol2rh), RAB11 family interacting protein 3 
non-metastatic cells 4 (Nme4), similar to Adenylosuccinate synthetase isoenzyme 
1 (LOC684425) and 0.81-0.69 –fold downregulation of nucleoside phosphorylase 
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(Np) and polymerase epsilon (Pole).  The second most significantly (P=0.014) 
enriched cell cycle pathway included 0.83-0.55 –fold downregulation in the 
following genes: cell division cycle 2, G1 to S and G2 to M (Cdc2 or Cdk1), 
minichromosome maintenance complex component 3 (Mcm3), minichromosome 
maintenance deficient 7 (Mcm7), E2F transcription factor 1 (E2f1), protein kinase, 
DNA activated catalytic polypeptide (Prkdc), anaphase promoting kinase inhibitor 
1B (Anapc1) and 1.20-1.24 fold upregulation of cyclin dependent kinase inhibitor 
1B (Cdkn1b) and origin recognition complex, subunit 3-like (Orc31). The third 
pathway included 8 significantly downregulated genes in the pathways in cancer 
with 0.71-0.80 –fold changes in colony-stimulating factor 1 receptor (Csf1r), GLI-
Kruppel family member GLI1 (Gli1), Collagen type IV, alpha 1 (Col4a1), Collagen 
type IV alpha 2 (Col4a2), laminin, alpha 4 (Lama4), E2F transcription factor 
(E2F1), MutS homolog 3 (E.coli) (Msh3), mechanistic target of rapamycin 
(mTOR). 
Levosimendan targeted common genes in MI and Sham rats; these included 
upregulation of 10 common genes including Arl6ip2, Atp5s, Cmbl, Cxcl11, 
LOC360830, LOC684270, Mlx, Mrpl41, RGD1309651, Vps28 and downregulation 
of 4 common genes namely Etv5, Lphn1, Paxip1 and Tln1.  
When I analysed which genes were downregulated in MI / Sham and upregulated 
by levosimendan in MI I found two genes, namely the 
carboxymethylenebutenolidase homologue (Cmbl) and the pleckstrin homology 
domain containing family f (Plekhf1) that fulfilled these criteria. Conversely one 
gene was shown to be downregulated by levosimendan that was upregulated in 
MI / Sham rats, namely the hydroxyprostaglandin dehydrogenase 15 (Hpgd) 
which encodes the NAD+-dependent 15-dehydroprostaglandin dehydrogenase 
enzyme (15-PGDH); a key inactivator of prostaglandins (Niesen et al. 2010). 
Discussion 
Diabetes is associated with an increase in fatty acid oxidation in the heart and MI 
is known to further impair myocardial energy metabolism (for a review, see 
Lopaschuk et al. 2002). The effect of levosimendan on genes  
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Table 4. Summary of results 
 Study 1 Study 2 Study 3 Study 4 
 
GK vs. 
Wistar 
GK MI vs. 
Wistar MI 
GK MI + 
Levo vs. 
GK MI 
GK 
SHAM + 
Levo vs. 
GK 
SHAM 
GK MI + 
Levo vs. 
GK MI 
GK 
SHAM + 
Levo vs. 
GK 
SHAM 
fP-Glucose ? ? ??? ??? ??? ??? 
S-Insulin ??? ? ??? ??? ??? ??? 
P-Renin 
activity 
??? ? ??? ??? ??? ??? 
Systolic BP ? ??? ??? ? ??? ??? 
Systolic 
function (EF%) 
? ??? ? ??? ? ??? 
LVH* ? ? ? ? ? ? 
P-BNP ? N/A ? ??? ? ??? 
ANP mRNA N/A ??? ? ??? ??? ??? 
Apoptosis 
(TUNEL) 
??? ? ? ??? N/A N/A 
Apoptosis# ? ? ? N/A N/A N/A 
Fibrosis¤ ??? ? ??? ??? ??? ??? 
CTGF mRNA ? ??? ? ??? N/A N/A 
pAkt/Akt 
protein 
N/A ? N/A N/A N/A N/A 
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 Study 1 Study 2 Study 3 Study 4 
 
GK vs. 
Wistar 
GK MI vs. 
Wistar MI 
GK MI + 
Levo vs. 
GK MI 
GK 
SHAM + 
Levo vs. 
GK 
SHAM 
GK MI + 
Levo vs. 
GK MI 
GK 
SHAM + 
Levo vs. 
GK 
SHAM 
pFOXO3a/ 
FOXO3a 
? ? N/A N/A N/A N/A 
DNA-bound 
FOXO3a& 
? ? ? N/A N/A N/A 
Sirt1 protein ? ? N/A N/A N/A N/A 
Acetyl p53/p53 ? ? N/A N/A N/A N/A 
p38 MAPK 
phosphory-
lation 
N/A ? N/A N/A N/A N/A 
? denotes increase, ? denotes decrease, ??? denotes no change, N/A (not 
available) parameter was not examined in the particular study, *as evaluated by 
average cardiomyocyte cross sectional area, #as evaluated by protein expression 
of Caspase-3, Bax or microarray of apoptosis specific gene expression, ¤as 
evaluated by collagen volume fraction, &as evaluated by electrophoretic mobility 
shift assay (EMSA), for a list of abbreviations refer to page 7.  
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implicated in energy metabolism such as the ATPase subunit were interesting and 
provide a new insight into the role of levosimendan in energy metabolism. Further, 
the mammalian target of rapamycin (mTOR) is a PI3K/Akt –activated transcription 
factor implicated in increased hypertrophy in cardiomyocytes (Shioi et al. 2002). 
Downregulation of mTOR by levosimendan in sham GK rats may, at least in part, 
explain the decrease in LVH seen here. 
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6 General discussion 
This study provides deeper insight into the molecular mechanisms of diabetic 
cardiomyopathy in the GK rat. The results showed that diabetic cardiomyopathy in 
GK rats was associated with some of the hallmarks found in diabetic subjects; 
namely left ventricular hypertrophy (LVH), apoptosis and fibrosis. In the studies I 
did not study diastolic dysfunction specifically, however study 1 indicated that 
systolic dysfunction may develop spontaneously in diabetic GK rats. The two 
other studies (2-3) showed no changes in systolic function between sham-
operated GK and Wistar however. These conflicting results show the difficulties 
and dispersion of results when using an inbred rat strain with a heterogenous 
genetic background in comparison to using e.g. single gene knock-out strains.  
Another issue with using spontaneously diabetic GK rats was that they developed 
modest hypertension at 8-9 weeks of age. This may have contributed to the 
development of LVH and the other parameters of diabetic cardiomyopathy. 
However the difference in blood pressure was modest and was absent in post-MI 
rats. Interestingly, systolic blood pressure was not affected by levosimendan in 
post-MI rats but did decrease slightly in sham-GK rats. However, these results 
provide the notion that the beneficial effects of levosimendan on LV remodelling 
were, at least in part, blood pressure independent. 
There are few studies regarding the involvement of stress response pathways 
FOXO3a and Sirt1 in diabetic cardiomyopathy. My results provided the first notion 
that FOXO3a and Sirt1 may be involved in the development of diabetic 
cardiomyopathy. Knowing that Sirt1 promotes growth, LVH in GK rats may be at 
least in part attributed to Sirt1 overexpression. Others have shown that insulin 
resistance in GK rats is associated with decreased phosphorylation of 
downstream kinases (Bitar et al. 2004; Desrois et al. 2004). Here I showed that 
this was associated with decreased cardioprotective Akt phosphorylation and 
concomitant proapoptotic FOXO3a activation in response to heart failure post-MI. 
These pathways may play important roles in the etiology of diabetes-induced 
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ventricular remodelling and provide part of the answer why diabetic subjects have 
increased morbidity and mortality after MI compared to non-diabetic ones. Earlier 
studies have shown the importance of ROS in the pathogenesis of GK rats (Bitar 
et al. 2004). One shortcoming of the current study was that I did not measure 
Sirt1 activation or the NAD+/NADH ratio in the cells that regulates Sirt1. Also I did 
not study the expression of Sirt1 in other metabolically crucial organs deeply 
involved in the diabetic pathogenesis such as skeletal muscle and liver. However, 
the results showed that p53-deacetylation at the Sirt1 –specific site was reduced 
indicating an increase in Sirt1 deacetylase activity was associated with increased 
protein expression. I did not study the acetylation of FOXO3a here, which should 
be done in future investigations. 
Levosimendan exerted several beneficial effects on ventricular remodelling such 
as decreased LVH (sham and MI rats), decreased apoptosis and senescence and 
decreased CTGF mRNA expression. Interestingly these changes were more 
prominent in diabetic GK rats. One may speculate that the underlying diabetic 
cardiomyopathy in GK rats which includes mitochondrial dysfunction, is an 
appreciative target for levosimendan which opens mitochondrial ATP –sensitive 
potassium channels. Also the involvement of PDE inhibition cannot be fully 
excluded. This finding warrants further research. The finding that levosimendan 
induced the Mas receptor and NEP enzyme and downregulated mTOR in sham-
operated GK rats was interesting; however the implications of these results were 
not totally clear. On the one hand, increased Ang(1-7) - Mas receptor activation 
and on the other downregulation of mTOR are, at least in theory, means by which 
levosimendan may have attenuated left ventricular hypertrophy seen here in GK 
sham rats. However, a shortcoming in the 4th study was that I did not examine the 
levels of tissue angiotensin II in the heart. A number of studies have shown the 
adverse effects of ROS accumulation in response to increased lipid oxidation in 
diabetes and in the post-MI condition. Here I found that levosimendan 
downregulated the gene expression of the Hpgd gene implicated in prostaglandin 
inactivation. Interestingly, the PPARgamma agonists, i.e. thiazolinediones, 
77 
 
including pioglitazone have been shown to inhibit Hpgd (Cho et al. 2002). 
Together with the notion that levosimendan was able to reduce LV remodelling in 
the diabetic rat this finding warrants further examination into the potential anti-
diabetic effects of levosimendan.  
In conclusion I have have shown here that spontaneously diabetic GK rats exhibit 
the traits required to examine diabetic cardiomyopathy in an animal model. The 
data indicate that cardioprotective mechanisms in the GK rat heart are impaired 
including changes in Akt – FOXO3a -signaling and p38 MAPK phosphorylation. 
Furthermore my results provide the notion that in the diabetic GK rat myocardium 
cardioprotecitve and prohypertrophic Sirt1 signalling is increased. Oral 
levosimendan for 4 and 12 weeks reduces ventricular remodelling and restores 
systolic function, by already known mechanisms and by its actions related to gene 
expression changes in the myocardium. 
6.1 Clinical implications and future perspectives 
Clinical implications of this study involve novel targets in the search of better 
treatment of complications due to diabetic cardiomyopathy, including FOXO3a, 
Sirt1 and p38. Here I have shown beneficial effects of oral treatment with 
levosimendan in reducing ventricular remodelling in diabetic cardiomyopathy. 
Since marketing authorisation, the use of levosimendan has increased steadily 
and is now approved in 47 countries worldwide. Today levosimendan is widely 
used in cardiac emergency units and is recoginsed as an alternative for the 
management of decompensated heart failure. Its off-label use is also gaining 
ground, including use in states such as septic shock, perioperative cardiac 
support and ischemic heart disease and cardiogenic schock. 
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7 Conclusions 
The aims of the studies were to investigate in more detail the molecular 
mechanisms ofdiabetic cardiomyopathy in spontaneously diabetic Goto-Kakizaki 
rats, a model of type 2 diabetes. Specifically I examined the role of Sirt1 – p53 
and Akt – FOXO3a pathways in the advent of ventricular remodelling. Ventricular 
remodelling in diabetic rats was further aggravated by experimental myocardial 
infarction. In this model of post-MI heart failure and ventricular remodelling I 
studied the cardiovascular effects of oral calcium sensitizer therapy with 
levosimendan. The main findings in the studies were: 
 
I. Ventricular remodelling in diabetic GK rats was associated with increased LVH, 
systolic dysfunction and increased apoptotic signalling and activation of the 
FOXO3a pathway. The study further suggested a role for Sirt1 in growth and 
counteracting apoptosis in diabetic cardiomyopathy. 
II. Post-myocardial infarction in GK rats was associated with increased LVH, 
sustained cardiomyocyte apoptosis and interstitial fibrosis. This study established 
the initial finding that FOXO3a activation was associated with Akt 
dephosphorylation after MI and that Sirt1 – p53 deacetylation was increased post-
MI. Furthermore, the data indicated that p38 MAPK protein phosphorylation was 
increased after MI in GK rat hearts. 
III. A 12 –week regimen of oral levosimendan exerted beneficial effects on 
ventricular remodelling by decreasing cardiomyocyte apoptosis, hypertrophy and 
markers of cellular senescence. The study provided a role for levosimendan in the 
treatment of diabetes-induced ventricular remodelling in post-MI heart failure. 
IV. The beneficial effects of levosimendan on systolic function and ventricular 
remodelling were evident at 4 weeks post-MI. The effects were associated with 
changes in the gene expression profile in the diabetic GK rat myocardium 
including downregulation of the hydroxyprostaglandin dehydrogenase 15 (Hpgd) 
gene and the mammalian target of rapamycin (mTOR) gene. 
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